

LUCIANA SALLES BRANCO DE ALMEIDA

Cirurgiã-dentista

**Atividade antimicrobiana dos extratos da *Rheedia
brasiliensis* e potencial anticárie do seu
composto bioativo**

Dissertação apresentada à Faculdade de Odontologia de Piracicaba, da Universidade Estadual de Campinas, para obtenção do título de Mestre em Odontologia, área de concentração Farmacologia, Anestesiologia e Terapêutica.

Orientador: Prof. Dr. Pedro Luiz Rosalen

PIRACICABA

2008

**FICHA CATALOGRÁFICA ELABORADA PELA
BIBLIOTECA DA FACULDADE DE ODONTOLOGIA DE PIRACICABA**

Bibliotecária: Marilene Girello – CRB-8ª. / 6159

AL64a	<p>Almeida, Luciana Salles Branco de. Atividade antimicrobiana dos extratos da <i>Rheedia brasiliensis</i> e potencial anticárie do seu composto bioativo. / Luciana Salles Branco de Almeida. -- Piracicaba, SP : [s.n.], 2008.</p> <p style="text-align: center;">Orientador: Pedro Luiz Rosalen. Dissertação (Mestrado) – Universidade Estadual de Campinas, Faculdade de Odontologia de Piracicaba.</p> <p style="text-align: center;">1. <i>Streptococcus mutans</i>. 2. Cárie dentária. I. Rosalen, Pedro Luiz. II. Universidade Estadual de Campinas. Faculdade de Odontologia de Piracicaba. III. Título.</p> <p style="text-align: right;">(mg/fop)</p>
-------	--

Título em Inglês: Antimicrobial activity of *Rheedia brasiliensis* extracts and anticaries potential of its bioactive compound

Palavras-chave em Inglês (Keywords): 1. *Streptococcus mutans*. 2. Dental caries

Área de Concentração: Farmacologia, Anestesiologia e Terapêutica

Titulação: Mestre em Odontologia

Banca Examinadora: Pedro Luiz Rosalen, Adriana Franco Paes Leme, Gilson César Nobre Franco

Data da Defesa: 22-02-2008


Programa de Pós-Graduação em Odontologia




UNIVERSIDADE ESTADUAL DE CAMPINAS
FACULDADE DE ODONTOLOGIA DE PIRACICABA



A Comissão Julgadora dos trabalhos de Defesa de Dissertação de MESTRADO, em sessão pública realizada em 22 de Fevereiro de 2008, considerou a candidata LUCIANA SALLES BRANCO DE ALMEIDA aprovada.



PROF. DR. PEDRO LUIZ ROSALEN



PROFa. DRa. ADRIANA FRANCO PAES LEME



PROF. DR. GILSON CÉSAR NOBRE FRANCO

Dedicatória

Aos meus queridos pais, **Francisco e Maria Eugênia**, os maiores orgulhos da minha vida, pelo amor, pelo exemplo, pela confiança nas minhas escolhas e pelo apoio de sempre.

Aos meus irmãos, **Francisco e Daniel**, por todos os momentos de alegria em família e, principalmente, pela nossa relação de carinho, respeito, companheirismo e amizade.

Ao **Bruno**, por ter trazido à minha vida mais amor e paz, muitas lições, apoio nos momentos difíceis, infinitos sonhos...e por ser a pessoa com quem desejo estar por toda a minha vida.

À **Carolina**, minha prima querida, por quem tenho um amor incondicional e com quem tive o prazer de conviver por tantos anos. Deixaste muitas saudades e, principalmente, uma lição de dignidade e luta pela vida.

Dedico a vocês, com todo o meu amor.

Agradecimentos especiais

A Deus, por ter me dado a vida e por tê-la mantido sempre com tantas alegrias e repleta de pessoas especiais.

Ao meu orientador e amigo, Prof. Dr. Pedro Luiz Rosalen, por ter me recebido como orientada, pelos anos de convivência e por todos os seus ensinamentos, que me fizeram evoluir pessoalmente e cientificamente.

Ao Prof. Dr. Marcelo Henrique dos Santos, por toda a colaboração dada à realização dos trabalhos e pela excelente orientação por todos esses anos.

Ao Prof. Dr. Hyun Koo (Michel) e ao Prof. Dr. Severino Alencar, por suas valorosas parcerias nos trabalhos.

Aos professores da área de Farmacologia, Anestesiologia e Terapêutica da FOP/UNICAMP, especialmente aos queridos mestres que tanto admiro: Prof^a. Dr^a. Maria Cristina Volpato, Prof. Dr. Eduardo Dias de Andrade e Prof. Dr. Francisco Carlos Groppo. Agradeço por todo o aprendizado que tive e pela convivência tão harmoniosa.

À Dr^a. Adriana Franco Paes Leme, por ter aceitado participar da minha formação e por sempre me ensinar, ajudar e incentivar de forma tão sábia e serena.

Ao meu futuro co-orientador de doutorado, Prof. Dr. Gilson César Nobre Franco, por quem tenho uma profunda admiração, carinho e respeito.

Aos membros da minha banca de qualificação, Profa. Dr^a. Cinthia Pereira Machado Tabchoury, Prof. Dr. Francisco Carlos Groppo e Dr^a. Rosângela Maria Neves Bezerra, por todas as valorosas contribuições a esse trabalho.

Agradecimentos especiais

Aos colegas que estão ou já passaram pela área de Farmacologia, Anestesiologia e Terapêutica e com quem tive o prazer de conviver: Myrella, Bruno, Ivy, Andreza, Cristiane, Karina, Michelle, Alcides, Humberto, Fernando, Luciana, Dani, Sidney, Paulo, Giovana, Márcia, Fábio, Regiane, Ramiro, Maíra, Simone, e Rogério. Agradeço pela união, pelos momentos de descontração, pela ajuda nos trabalhos e por tornarem minhas idas à FOP sempre tão alegres.

Aos amigos de todas as horas: Myrella, Cristiane, Karina e Bruno. Obrigada pela companhia e pela amizade. Vocês são muito especiais pra mim!

Aos amigos Ramiro e Regiane, com quem mantive, desde o início, uma grande parceria nos trabalhos do laboratório e nos momentos de festa. Obrigada por terem me dado apoio e terem me ensinado tantas coisas.

À Eliane, amiga e companheira de todos os momentos no laboratório. Serei sempre grata por tudo que aprendi com você pessoalmente e profissionalmente.

À Carol Nóbrega, com quem tive o prazer de trabalhar em parceria na sua tese. Posso dizer que você fez parte da minha formação e que me serviu de exemplo pela coragem, competência e sabedoria.

À Elisa, excelente secretária do nosso curso, por sempre se mostrar disposta a ajudar, pela sua simpatia e pela sua amizade.

Ao técnico José Carlos, pela sua ajuda nos trabalhos do laboratório.

Agradecimentos especiais

Ao Prof. Dr. Ricardo Antunes de Azevedo, pela oportunidade de trabalhar no Laboratório de Genética e Bioquímica de Plantas da ESALQ-USP, e às amigas Paula e Giselle, por toda a ajuda nos experimentos.

Aos colegas de turma do curso de Especialização em Periodontia da FOP, Carolina, Cristina, Thaís, Karla, Verônica, Fernanda, Fabrícia, Camila, Mauro, Roberto e Rogério, por terem sido responsáveis por tantos momentos de alegrias nos primeiros anos em Piracicaba. E aos professores, Dr. Vinícius, Dr. Jorge e Dr. Edwil, por terem contribuído imensamente para a minha formação clínica.

À dona Eliana e toda a sua família, por terem me recebido e tratado como um membro da família durante os tempos do pensionato.

Às queridas amigas que moraram comigo no pensionato da Eliana e de quem sinto muitas saudades: Carol Nóbrega, Daniela, Paula, Jéssica e Viviane. Obrigada por terem me dado a companhia e o carinho que tanto precisei na minha chegada em Piracicaba. Saudades.

Às companheiras e amigas-irmãs com quem dividi a mesma casa nos inesquecíveis tempos da nossa tão animada república: Liana, Patrícia (Patfu), Vanessa (Ruiva), Susana, Daniela, Mônica e Gisele. Obrigada por tudo!

Às amigas Liana, Regiane, Patrícia (Patfu), Daiane, Alynne e Bia, por todos os nossos momentos juntas e pelas demonstrações de sincera amizade. Muitas saudades sempre.

Aos amigos Marcelo Goiano, Guilherme, Marcelo Santista, Andréia, Cléverson e Bruno Gurgel, por terem trazido tão bons momentos durante nossa intensa convivência.

Aos colegas, funcionários e professores da área de Cariologia, por todos os bons momentos e por sempre me receberem bem no laboratório de Bioquímica.

Agradecimentos especiais

Ao Jorge Valerio, pela amizade, pelos momentos de descontração e por toda a contribuição na escrita dos trabalhos.

Aos meus alunos do cursinho da FOP/UNICAMP, por terem feito parte da minha experiência como docente e por terem me recebido de braços abertos.

Aos queridos amigos de São Luís que estão sempre torcendo por mim, apesar da distância: Letícia, Camila, Carol, Flávia Tereza, Lorena, Aléssio, Carol Padilha, Eliane, Valquíria e Cecília.

Ao meu orientador de iniciação científica e eterno amigo, Prof. Dr. Antônio Luiz Amaral Pereira, pelo apoio e por sempre me servir de exemplo em todos os meus caminhos.

À toda a minha família que, apesar da distância, sempre me acompanhou com muito carinho e me apoiou nas minhas escolhas.

À Rita, ao Juliano, à Fabiana e à Fernanda, por todos os bons momentos e por serem a minha segunda família, ajudando-me a superar a saudade dos meus familiares.

Agradecimentos

À Universidade Estadual de Campinas, por meio do reitor **Prof. Dr. José Tadeu Jorge**.

À Faculdade de Odontologia de Piracicaba (FOP-UNICAMP), na pessoa do diretor **Prof. Dr. Francisco Haitter Neto**.

Ao coordenador dos Cursos de Pós-Graduação da Faculdade de Odontologia de Piracicaba, **Prof. Dr. Mário Alexandre Coêlho Sinhoreti**.

À **Prof^a. Dr^a. Fernanda Klein Marcondes**, chefe do departamento de Ciências Fisiológicas da Faculdade de Odontologia de Piracicaba.

À **Prof^a. Dr^a. Cláudia Herrera Tambeli**, coordenadora do Curso de Pós-Graduação em Odontologia.

Ao **Prof. Dr. Pedro Luiz Rosalen**, coordenador da área de Farmacologia, Anestesiologia e Terapêutica.

Ao **CNPq**, Conselho Nacional de Desenvolvimento Científico e Tecnológico, pela concessão da bolsa de estudo para a realização deste trabalho.

À **FAPESP**, Fundação de Amparo à Pesquisa do Estado de São Paulo, pelo auxílio à pesquisa para o desenvolvimento dos trabalhos.

Agradecimentos

À **Sr^a. Érica Alessandra Sinhoreti** e à **Sr^a. Raquel Quintana Sachi**, membros da Coordenadoria do Programa de Pós-Graduação da FOP-UNICAMP, pela solicitude e presteza de seus serviços.

“O mais importante da vida não é a situação em que estamos, mas a direção para a qual nos movemos.”

(Oliver Wendell Holmes)

Resumo

Este estudo avaliou a atividade antimicrobiana de extratos da *Rheedia brasiliensis* contra *Streptococcus mutans* e o potencial anticárie do seu composto ativo isolado. Os extratos hexânicos (EH), acetato de etila e etanólico (concentrações entre 6,25-800 µg/ml) do fruto (“bacupari”) foram testados contra *S. mutans* UA159 por meio de determinação das concentrações inibitória mínima (CIM) e bactericida mínima (CBM). Biofilmes de 5 dias de formação foram tratados com os extratos ativos (100 x CIM), por 0, 1, 2, 3 e 4 h, e plaqueados para contagem das UFC/ml (*time kill*). Os extratos ativos foram submetidos à análise química por métodos espectroscópicos, e o composto ativo isolado (0,625-80 µg/ml) foi testado contra células de *S. mutans* por meio de CIM/CBM. A influência do composto isolado (12,5-100 µg/ml) sobre a síntese de glucanos foi avaliada através da atividade da enzima glucosiltransferase (GTF) B em superfície de hidroxiapatita. A ação do composto sobre biofilmes (125 e 250 µg/ml) foi testada com os ensaios de queda de pH e inibição de formação de biofilme. O potencial anticárie do composto (250 µg/ml) foi avaliado em ratas *Wistar* sob alto desafio cariogênico. Os EH (casca e semente) inibiram *S. mutans* em baixas concentrações (CIM:12,5-25 µg/ml) e reduziram células viáveis dos biofilmes após 4 h de exposição. O composto ativo presente foi identificado como a 7-epiclusianona (7-epi), a qual inibiu o crescimento do *S. mutans* (CIM:1,25-2,5 µg/ml), a atividade da GTF B em superfície (48% de inibição) e a produção de ácidos do *S. mutans* em biofilme, porém não reduziu a formação e o acúmulo dos biofilmes. No estudo animal, a 7-epi reduziu a incidência e a severidade de cárie e a microbiota total, mas não diminuiu a porcentagem de *S. mutans*. A 7-epi diminuiu a virulência do *S. mutans* e inibiu o desenvolvimento de cárie *in vivo*, sugerindo ser um agente terapêutico promissor para o controle do biofilme dental cariogênico.

Palavras-chave: *Rheedia brasiliensis*, 7-epiclusianona, *Streptococcus mutans*, fatores de virulência, cárie animal.

Abstract

The present study evaluated the antimicrobial activity of *Rheedia brasiliensis* extracts against *Streptococcus mutans* and the anticaries properties of its isolated bioactive compound. Hexane (HE), ethyl-acetate and ethanolic extracts (concentrations ranging from 6.25 to 800 µg/ml) of *R. brasiliensis* fruits (“bacupari”) were tested against *S. mutans* UA159 by determining the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). *S. mutans* 5-days-old biofilms were treated with active extracts (100 x MIC), for 0, 1, 2, 3 e 4 h (time-kill), and plated for colony counting (UFC/ml). Such extracts were submitted to exploratory chemical analyses to isolate and identify the bioactive compound using spectroscopic methods. The compound (0.625-80 µg/ml) was then tested against *S. mutans* cells using MIC/MBC assays. The influence of the bioactive compound (12.5-100 µg/ml) on glucans synthesis was evaluated by testing the activity of glucosyltransferase (GTF) B on hydroxyapatite surface. The effects of the compound (125 e 250 µg/ml) on biofilms were analyzed using glycolytic pH-drop and inhibition of formation assays. The anticaries activity of such compound (250 µg/ml) was evaluated in *Wistar* rats submitted to a high cariogenic challenge. HE (peel and seeds) reduced *S. mutans* cells at low concentrations (MIC:12.5-25 µg/ml) and also biofilm viability after four hours, confirming the presence of the bioactive compound. This compound was identified as 7-epiclusionone (7-epi), which inhibited the *S. mutans* growth (MIC:1.25-2.5 µg/ml), the activity of GTF B (48% of inhibition) and the acid production, not interfering with the formation and accumulation of biofilms. In the animal study, 7-epi additionally reduced the incidence and severity of caries and also the total microbiota, however no reduction on the percentage of *S. mutans* was observed. In conclusion, 7-epi may be considered a promising agent to control cariogenic dental biofilm.

Keywords: *Rheedia brasiliensis*, 7-epiclusionone, *Streptococcus mutans*, virulence factors, animal caries.

Sumário

INTRODUÇÃO	1
CAPÍTULOS	5
CAPÍTULO 1: “Antimicrobial activity of <i>Rheedia brasiliensis</i> and 7-epiclusianone against <i>Streptococcus mutans</i> .”	6
CAPÍTULO 2: “Effects of 7-epiclusianone on <i>Streptococcus mutans</i> and its anticaries activity in rats.”	23
CONCLUSÕES	43
REFERÊNCIAS	44
APÊNDICE: Desenhos esquemáticos dos métodos de obtenção dos extratos e da 7-epiclusianona a partir do fruto da <i>Rheedia brasiliensis</i> (bacupari)	48
ANEXOS	49
ANEXO 1: Resolução do formato alternativo para defesa da dissertação de mestrado	49
ANEXO 2: Certificado de aprovação do Comitê de Ética em Pesquisa – Faculdade de Odontologia de Piracicaba – FOP/UNICAMP	51
ANEXO 3: Certificado de aprovação do Comitê de Ética na Experimentação Animal – Faculdade de Odontologia de Piracicaba – FOP/UNICAMP	52
ANEXO 4: E-mail de confirmação de aceite do artigo referente ao Capítulo 1	53
ANEXO 5: Declaração dos autores referente a direitos autorais	54
ANEXO 6: Declaração da revista <i>Phytomedicine</i> referente a direitos autorais	55

1 Introdução

Apesar dos avanços na redução de sua prevalência, a cárie dental continua sendo considerada uma das infecções bucais mais comuns, afetando diversas populações no mundo (Bowen, 2002). A cárie ocorre pela ação de bactérias acidogênicas e acidúricas (Hamada & Slade, 1980), especialmente estreptococos do grupo mutans, que interagem numa comunidade mista, formando um biofilme tridimensional na superfície dental (Marsh, 2003). Esses microrganismos organizam-se funcionalmente no interior de uma matriz extracelular e são capazes de modificar o ambiente para favorecer seu crescimento e sua sobrevivência (Davey & O'Toole, 2000).

O *Streptococcus mutans*, bactéria do grupo mutans associada ao início da doença cárie (Loesche, 1986), possui importantes características fisiológicas reconhecidas como fatores de virulência. Essa bactéria é capaz de metabolizar diversos carboidratos presentes na dieta e de produzir ácidos orgânicos (acidogenicidade) que são liberados na matriz do biofilme. O *S. mutans* possui, também, a capacidade de sobreviver em meio ácido (aciduricidade), através dos mecanismos de translocação de prótons pela enzima F-ATPase (H^+ -ATPase), que bombeia prótons para o meio extracelular, e pela provável inibição de enzimas glicolíticas intracelulares, sensíveis ao pH mais ácido, o que pode reduzir a capacidade de produção de ácidos por esses microrganismos (Marquis *et al.*, 2004).

Além da acidogenicidade e da aciduricidade, a capacidade de sintetizar glucanos, na presença de sacarose, representa um outro importante fator de virulência associado ao *S. mutans*. Os glucanos são produzidos a partir da ação de três enzimas glucosiltransferases (GTFs): GTF B, responsável pela produção de glucanos insolúveis em água; GTF C, responsável pela produção de glucanos solúveis e insolúveis; e GTF D, responsável, exclusivamente, pela produção de glucanos solúveis (Loesche, 1986). Por estar relacionada à síntese de glucanos insolúveis extracelulares, a GTF B tem sido considerada a enzima de maior importância na patogênese da cárie dental (Yamashita *et al.*, 1993). A síntese de glucanos possibilita a aderência do *S. mutans* à superfície dos dentes (Burne *et al.*, 1999; Wunder & Bowen, 1999), permitindo, assim, que a bactéria reduza o pH do biofilme dental a valores inferiores a 5 (Belli & Marquis, 1991), levando à desmineralização dos tecidos dentais e iniciando o processo da cárie (Bowden, 1990).

Além das reconhecidas medidas de prevenção da cárie dental, como os procedimentos mecânicos de remoção do biofilme cariogênico, a adequação da dieta e o uso do flúor (Tinanoff *et al.*, 2002), tem-se investigado novas estratégias, buscando-se evitar os prejuízos trazidos pela doença, incluindo dor, comprometimento estético, alto custo do tratamento odontológico e/ou perdas dentais. Dentre as estratégias, tem-se destacado a redução de patógenos específicos relacionados à cárie por meio de agentes antimicrobianos capazes de inibir o crescimento de estreptococos do grupo mutans ou de agir sobre fatores de virulência dessas bactérias (Koo *et al.*, 2002; Baehni & Takeuchi, 2003).

A busca por novos agentes com ação sobre patógenos orais tem estimulado a pesquisa com produtos de origem natural, incluindo as plantas medicinais. Uma grande porcentagem das novas moléculas descobertas, com vistas à sua introdução na indústria farmacêutica, provém de constituintes de plantas e/ou derivados semi-sintéticos (Newman & Cragg, 2007). Considerando-se que novos produtos de origem natural com atividade sobre patógenos orais podem ser de grande importância para prevenção e controle de doenças bucais infecciosas, incluindo a cárie dental, estudos recentes apresentaram efeitos de compostos bioativos sobre fatores de virulência de estreptococos do grupo mutans, apresentando potencial antimicrobiano e anticárie (Koo *et al.*, 2000; Duarte *et al.*, 2003; Duarte *et al.*, 2006). Assim, extratos ou substâncias isoladas de plantas medicinais ou de outros produtos encontrados na natureza podem ser pesquisados como alternativas terapêuticas para o controle do biofilme dental cariogênico (Tichy & Novak, 1998).

O Brasil apresenta uma enorme diversidade de plantas medicinais, cujos extratos vegetais têm sido empiricamente utilizados na medicina popular para o tratamento de diversas doenças (Braz-Filho, 1999). Tais aplicações são possíveis graças à ação de substâncias ativas presentes nos extratos utilizados (Newman & Cragg, 2007). Dentro da diversidade química de produtos naturais brasileiros, a família Guttiferae destaca-se pela enorme variedade de gêneros (cerca de 47), tais como *Rheedia*, *Vismia*, *Clusia*, *Cratogeomys*, *Harungana*, *Mesua*, *Hypericum* e *Kielmeyera*, responsáveis pela existência de mais de 1.000 espécies na família (Piccinelli *et al.*, 2005).

O gênero *Rheedia* (sinônimo: *Garcinia*) é considerado o de maior número de

espécies da família Guttiferae (Morton, 1987). Análises químicas de partes de plantas desse gênero apresentaram uma composição química variada, com predomínio de derivados fenólicos prenilados e oxigenados (Piccinelli *et al.*, 2005), incluindo benzofenonas polipreniladas (Dos Santos *et al.*, 1999; Rubio *et al.*, 2001). Benzofenonas polipreniladas isoladas da família Guttiferae têm demonstrado potencial antimicrobiano sobre cocos gram-positivos, gram-negativos e fungos (Bakana *et al.*, 1987; Rubio *et al.*, 1999), *Actinomyces* sp. (Rubio *et al.*, 1999), *Staphylococcus aureus* (Hussain *et al.*, 1982; Iinuma *et al.*, 1996; Santos *et al.*, 1996), *Trypanosoma cruzi* (Alves *et al.*, 1999), e *Helicobacter pylori* (Chatterjee *et al.*, 2003), além de outras propriedades farmacológicas, tais como ações anti-câncer (Ito *et al.*, 2003), anti-HIV (Gustafson *et al.*, 1992), anti-ulcerativa (Yamaguchi *et al.*, 2000) e vasculares (Cruz *et al.*, 2007). Entretanto, ainda não há estudos na literatura avaliando a ação antimicrobiana de benzofenonas polipreniladas sobre bactérias causadoras de infecções bucais, incluindo a cárie dental.

Algumas pesquisas envolvendo o gênero *Rheedia* investigaram propriedades biológicas de suas espécies (Weng *et al.*, 2004; Dharmaratne *et al.*, 2005; Cruz *et al.*, 2007); no entanto, existem poucos estudos relacionados à atividade antimicrobiana de extratos ou compostos extraídos desse grupo de plantas. Dos Santos (1996), baseando-se nos estudos prévios de Delle Monache *et al.* (1983), analisou quimicamente o extrato hexânico de uma planta do gênero *Rheedia* e isolou alguns constituintes químicos de partes do seu fruto: o extrato hexânico do pericarpo (casca) apresentou um novo composto poliprenilado, denominado 7-epiclusianona, além de uma fração contendo os sesquiterpenos α -copaeno, α -muuroleno, γ -cadineno e cadineno (Dos Santos *et al.*, 1999). A 7-epiclusianona teve seus efeitos biológicos investigados em estudos *in vitro*, demonstrando potencial contra agentes patogênicos, como fitobactérias, *S. aureus* e *T. cruzi* (Santos *et al.*, 1996; Alves *et al.*, 1999). Estudos *in vivo* (modelo animal) investigaram outras ações da 7-epiclusianona, incluindo potencial antitumoral (Alves *et al.*, 1999) e ações vasculares (Cruz *et al.*, 2007).

Estudos preliminares recentes realizados pelo nosso grupo de pesquisa avaliaram a atividade antimicrobiana dos extratos da *Rheedia brasiliensis* (sinônimo: *Garcinia brasiliensis*) (Almeida *et al.*, 2005; Murata *et al.*, 2006), planta nativa da região

amazônica brasileira. Considerada a espécie mais conhecida do gênero *Rheedia* (Morton, 1987) e também chamada de “bacupari”, essa planta tem sido utilizada na medicina popular como agente cicatrizante e no tratamento de úlceras pépticas e tumores (Corrêa, 1978).

Extratos hexânicos provenientes do fruto da *R. brasiliensis* demonstraram atividade antimicrobiana contra *S. mutans*, tendo sido capazes de atuar em baixas concentrações (CIM¹: 12,5-25 µg/ml) (Almeida *et al.*, 2005; Murata *et al.*, 2006). Os resultados indicaram uma característica apolar para o composto ativo, sugerindo a presença de compostos prenilados, como os encontrados em outra espécie semelhante já analisada quimicamente (Dos Santos *et al.*, 1999), incluindo a benzofenona poliprenilada 7-epiclusianona. No entanto, apesar da ação antimicrobiana promissora, os extratos ativos da *R. brasiliensis* ainda não haviam sido quimicamente analisados para identificação de seu composto ativo contra *S. mutans* até a realização do presente estudo

Sendo assim, os objetivos desse estudo foram: 1) analisar a atividade dos extratos do fruto da *Rheedia brasiliensis* contra *Streptococcus mutans*; 2) isolar e identificar o composto bioativo contra *S. mutans*; 3) avaliar a influência do composto bioativo sobre fatores de virulência do *S. mutans*; 4) determinar a capacidade do composto bioativo em prevenir ou reduzir a incidência de cárie dental *in vivo* (modelo animal).

¹ CIM – Concentração Inibitória Mínima.

2 Capítulos

Esta dissertação está baseada na Informação CCPG/002/06/UNICAMP, que regulamenta o formato alternativo para a dissertação de Mestrado e permite a inserção de artigos científicos de autoria ou co-autoria do candidato (Anexo 1).

Desta forma, esta tese é composta de 2 estudos em formato de artigos, sendo 1 já aceito para publicação e outro ainda em fase de submissão, cujos títulos estão descritos a seguir:

2.1 Capítulo 1: “Antimicrobial activity of *Rheedia brasiliensis* and 7-epiclusianone against *Streptococcus mutans*”, o qual foi aceito para publicação na revista *Phytomedicine* (Anexo 4).

2.2 Capítulo 2: “Effects of 7-epiclusianone on *Streptococcus mutans* and its anticaries activity in rats”, o qual se apresenta em fase de submissão.

2.1. Capítulo 1:

Antimicrobial activity of *Rheedia brasiliensis* and 7-epiclusianone against *Streptococcus mutans*

L.S.B. Almeida^a, R.M. Murata^a, R. Yatsuda^b, M.H. Dos Santos^c, T.J. Nagem^d, S.M. Alencar^e, H. Koo^f, P.L. Rosalen^{a,*}

^aDepartment of Physiological Sciences, Faculty of Dentistry of Piracicaba, State University of Campinas, SP, Brazil;

^bCenter of Technology in Health, Federal University of Bahia, Vitória da Conquista, BA, Brazil;

^cLaboratory of Phytochemistry and Medicinal Chemistry, Federal University of Alfenas, MG, Brazil;

^dDepartment of Chemistry - ICEB, Federal University of Ouro Preto, MG, Brazil;

^eDepartment of Agri-Food industry, Food and Nutrition, Escola Superior de Agricultura Luiz de Queiroz, University of São Paulo, Piracicaba, SP, Brazil;

^fCenter for Oral Biology and Eastman Department of Dentistry, University of Rochester Medical Center, Rochester, NY, USA.

***Corresponding author:**

Tel.: +551921065313 / Fax.: +551921065218

E-mail address: rosalen@fop.unicamp.br

Abstract

This *in vitro* study evaluated the antimicrobial activity of extracts obtained from *Rheedia brasiliensis* fruit (“bacupari”) and its bioactive compound against *Streptococcus mutans*. Hexane, ethyl-acetate and ethanolic extracts obtained (concentrations ranging from 6.25 to 800 µg/ml) were tested against *S. mutans* UA159 using MIC/MBC assays. *S. mutans* 5-days-old biofilms were treated with the active extracts (100 x MIC) for 0, 1, 2, 3 and 4 hours (time-kill) and plated for colony counting (CFU/ml). Active extracts were submitted to exploratory chemical analyses so as to isolate and identify the bioactive compound using spectroscopic methods. The bioactive compound (concentrations ranging from 0.625 to 80 µg/ml) was then tested using MIC/MBC assays. Peel and seed hexane extracts showed antimicrobial activity against planktonic cells at low concentrations and were thus selected for the time kill test. These hexane extracts reduced *S. mutans* biofilm viability after four hours, certifying of the bioactive compound presence. The bioactive compound identified was the polyprenylated benzophenone 7-epiclusianone, which showed a good antimicrobial activity at low concentrations (MIC: 1.25-2.5 µg/ml; MBC: 10-20 µg/ml). The results indicated that 7-epiclusianone may be used as a new agent to control *S. mutans* biofilms; however, more studies are needed to further investigate the mechanisms of action and the anticariogenic potential of such compound found in *R. brasiliensis*.

Keywords: *Rheedia brasiliensis*; Antimicrobial activity; 7-epiclusianone; *Streptococcus mutans*.

Introduction

Despite the advances concerning its prevention and control, dental caries is still considered a public health problem that affects many countries in the world (Bowen, 2002). Dental caries occurs by the action of acidogenic and aciduric bacteria (Hamada and Slade, 1980), which interact with other microorganisms in biofilms on dental surfaces (Marsh, 2003). Because of their role in the process of dental caries disease, some mutans streptococci have been extensively studied regarding their actions in dental biofilm and their virulence factors, including their acid tolerance and synthesis of insoluble glucans (Duarte et al., 2003; Lemos et al., 2005). The *Streptococcus mutans* is an important pathogen related to the initiation of dental caries in animals and humans (Loesche, 1986). It occurs specially because of its capability of sucrose-dependent adhesion and acid production, which leads to the consequent enamel demineralization (Belli and Marquis, 1991; Paes Leme et al., 2006).

The reduction in bacterial biofilm or specific pathogens associated with caries lesion using therapeutic agents with action against *S. mutans* and its virulence factors is a very common, effective approach for the prevention and control of caries (Baehni and Takeuchi, 2003).

Many studies on caries-related microorganisms have shown that some natural products can interfere with survival and virulence factors of *S. mutans*. A remarkable anticariogenic potency was also observed for natural bioactive compounds tested *in vitro* and *in vivo* (Koo et al., 2002a, 2003; Yatsuda et al., 2005; Duarte et al., 2006). Thus, medicinal plants are a potential source of biomolecules that must be investigated as an adjunctive therapy to control cariogenic dental biofilms.

The great biodiversity of plants found in Brazil might serve as an important source of new pharmacological agents (Basso et al., 2005). The Guttiferae represents a large family of medicinal plants with approximately 1,350 species, many of which are known for their fine-flavored fruits (Campbell, 1996). In addition, some genus, such as *Rheedia*, have many types of substances with various pharmacological properties (Bakana et al., 1987; Delle Monache et al., 1991; Gustafson et al., 1992; Dos Santos, 1996; Yamaguchi et al., 2000; Ito et al., 2003).

Previous studies have reported the presence of flavonoids, xanthenes and polyprenylated benzophenones in some species of *Rheedia*, by analyzing their chemical constituents (Delle Monache et al., 1983; Dos Santos et al., 1999). One class of these compounds, the polyprenylated benzophenones, showed good antibacterial activity against important pathogens (Dos Santos, 1996; Alves et al., 1999), suggesting that *Rheedia* is a promising chemical medicinal genus.

Rheedia brasiliensis Planch. & Triana (Syn. *Garcinia brasiliensis* Mart.), considered a very known species of genus *Rheedia*, is a plant native to the Amazon region. Its fruit is popularly known as “bacupari” or “bacoparé” and is widely used in folk medicine and also by natives of that region to prepare candies and medicines (Corrêa, 1978; Morton, 1987).

Since no studies on *R. brasiliensis* activity against oral pathogens were found in the literature, the present study analyzed the activity of *R. brasiliensis* fruit extracts against *Streptococcus mutans* and also the isolation and identification of the bioactive compound obtained from the active fraction.

Materials and methods

Plant material

Extracts and 7-epiclusianone

R. brasiliensis fruits were collected from trees grown under controlled conditions at the herbarium of the University of Viçosa (latitude 20°45'14" south and longitude 42°52'55" west), Minas Gerais, Brazil, where its voucher specimen is deposited (number VIC2604). To obtain the extracts, the peel and the seeds were dried and powdered, and then treated with *n*-hexane at room temperature to allow chemical fractioning based on the polarity gradient of such solvents as hexane, ethyl-acetate and ethanol (peel) and hexane (seed), using the Soxhlet equipment for 24 hours (Dos Santos et al., 1999). Each extract concentration was obtained under reduced pressure to allow peel extracts from hexane, ethyl-acetate and ethanol and seed extract from hexane, which were finally chromatographed as described by Dos Santos et al. (1999). To obtain the bioactive compound, peel hexane extract (PHE) and seed hexane extract (SHE) were

chromatographed on a silica gel column and eluted with crescent polarity mixtures of *n*-hexane/ethyl-acetate and ethyl-acetate/ethanol. Its structure was identified as the polyprenylated benzophenone 7-epiclusianone [m.p. 92-93 °C (MeOH); $[\alpha]_D^{25} +77$ (*c* 0.1, CHCl₃)] (Fig. 1) using several spectroscopic techniques (IR, UV, MS and NMR). The data were compared with those verified in a previous study investigating the chemical structure of this compound (Dos Santos et al., 1998, 1999). The purity (99.85%) of the bioactive compound and the retention time (17.961 minutes in peel hexane extract and 17.959 minutes in seed hexane extract) were determined by HPLC (Shimadzu LC-10A), using a C18 column (150mm-4.6mm) with a 5- μ m particle size (Fig. 2). The suitable gradient was achieved using MeOH:acetic acid 5%, pH 3.84, (40:60 v/v) to MeOH 100% for 10 min, with a solvent flow rate of 1.2 mL/min, at 30 °C, $\lambda=254$ nm. ClassVP-LC10 software was used for data collection.

For the antimicrobial assays, the extracts and 7-epiclusianone were dissolved in 80% ethanol just prior to the microbiological tests, which were also used to monitor the biological activity of the extracts during the extraction process.

Bacterial strain

The bacterial strain used in this experiment was *Streptococcus mutans* UA159, a proven cariogenic dental pathogen (Ajdic et al., 2002). The cultures were stored at -80 °C in Brain Heart Infusion (BHI) containing 20% glycerol (v/v).

Antimicrobial activity assays

Determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC)

The antimicrobial activity of *R. brasiliensis* extracts was first evaluated by determining MIC and MBC, according to the methodology described by Pidcock (1990) and Phillips (1991). Concentrations of the extracts tested ranged from 6.25 to 800 μ g/ml. 7-epiclusianone was tested in concentrations ranging from 0.625 to 80 μ g/ml. MIC was

defined as the lowest concentration of the agents tested showing restricted growth at a lower level than 0.05 at 660 nm (no visible growth).

To determine MBC, an aliquot (50 μ l) of each incubated tube containing suspension with extracts and compound at concentrations higher than the MIC was subcultured on BHI agar supplemented with 5% defibrinated sheep blood using a Spiral Plater (Whitley Automatic Spiral Plater). MBC was defined as the lowest concentration that allowed no visible growth on the agar (99.9% killed) (Koo et al., 2000). Three replicates were made for each agent tested and for all assays. Chlorhexidine digluconate 0.12% (v/v) (Sigma[®]) was used as positive control for determining MIC and MBC.

Bacterial viability in biofilm

Bacterial viability test was carried out before the isolation and identification of the bioactive compound. The peel hexane and seed hexane extracts showed antimicrobial activity against planktonic cells. Thus, the bacterial viability analysis of *S. mutans* biofilms, considering time-kill assay, yielded complementary data for MIC and MBC.

Biofilms were formed on standard glass microscope slides in batch cultures for 5 days (Koo et al., 2002a). The 5-days-old biofilms were exposed to the extracts tested (final concentrations of 100 x MIC) for 0, 1, 2, 3 and 4 hours. Every one hour starting at baseline, the biofilms were removed, suspended in salt solution (50 mM KCl and 1 mM MgCl₂, pH 7.0) and subjected to sonication twice, each consisting of three 10-s pulses, at 5-s intervals, at 50 W. Then, the homogenized suspension was serially diluted (10^1 , 10^2 , 10^3 and 10^4) and plated on Tryptic Soy Agar (TSA) using a Spiral Plater (Whitley Automatic Spiral Plater). The plates were incubated in 5% CO₂, at 37 °C, for 48 h, and then colony forming units per ml (CFU/ml) were quantified.

Killing curves were constructed by plotting values in the ordinate label: N_0 stands for the original number of CFU/ml; N stands for the number after the times of exposure. The assays were made in duplicate on at least three different occasions. A bactericidal effect was defined as a decrease in the CFU/ml ($\log N/N_0 > 3$) from initial viable counts at baseline (Koo et al., 2002b). Chlorhexidine digluconate 0.12% (v/v) (Sigma[®]) was used as positive control for the time-kill assay.

Results

Effect of agents on planktonic cells

The effect of the *R. brasiliensis* fruit extracts on *S. mutans* planktonic cells is shown in Table 1. Among the extracts tested, the peel hexane and seed hexane extracts presented a potential antibacterial activity against *S. mutans* at low concentrations (seed hexane extract – MIC: 12.5-25 µg/ml/ MBC: 50-100 µg/ml; peel hexane extract – MIC: 12.5-25 µg/ml/ MBC: 25-50 µg/ml). The ethanol and ethyl-acetate peel extracts displayed no inhibitory activity against the microorganism tested.

The isolated bioactive compound 7-epiclusianone presented lower MIC/MBC values (1.25-2.5 µg/ml and 10-20 µg/ml, respectively) than those found for the active extracts (Table 1). Chlorhexidine showed MIC/MBC values of 1-2 µg/ml and 8 µg/ml, respectively.

Effect of extracts on biofilm viability

Among the extracts tested for antimicrobial activity, only the bioactive extracts, such as peel hexane and seed hexane extracts, were tested in a biofilm model using the time-kill analysis (Fig. 3). These extracts, at a concentration of 100 x MIC (2500 µg/ml or 2.5 mg/ml), reduced viable counts of *S. mutans* UA159. However, only the seed hexane extract was able to decrease the log N/N₀ > 3 units after 4 h exposure. Chlorhexidine 0.12%, showed total bactericidal effect after 2 h exposure (Fig. 3).

Discussion

It is well known that most of the new drugs discovered in the last few decades have originated from the nature (Newman and Cragg, 2007). Chemical constituents obtained from medicinal plants and other natural products have been increasingly used to treat many infectious diseases. Since dental caries is considered one of the most common infectious disease of mankind (Smith, 2002), many studies have been aimed at identifying compounds from natural products against mutans streptococci, specially *Streptococcus*

mutans (Tichy and Novak, 1998; Badria and Zidan, 2004; Yatsuda et al., 2005; Duarte et al., 2006).

The present study showed that hexane extracts obtained from peel and seeds of *Rheedia brasiliensis* fruit, a member from Guttiferae family, showed a potential activity against *S. mutans* at low concentrations, showing the same MIC values. According to Rios et al. (1988), natural extracts that exhibit activity at concentrations lower than 100 µg/ml could have great antimicrobial potential, since the active compounds can be isolated and used at lower concentrations.

Of all the species identified in Brazil, the Guttiferae family is outstanding for its great number of pharmacological properties and bioactive compounds from its species. Some polyprenylated benzophenone derivatives obtained from Guttiferae have been reported as having potential antimicrobial activity against gram-positive and gram-negative cocci, mycobacteria and fungi (Bakana et al., 1987), *Staphylococcus aureus* (Inuma et al., 1996; Dos Santos et al., 1996), *Trypanosoma cruzi* (Alves et al., 1999) and *Helicobacter pylori* (Chatterjee et al., 2003). However, Guttiferae antimicrobial activity against oral microorganisms had never been investigated.

Our study showed that, in addition to their ability to inhibit planktonic cells, the hexane extracts tested reduced the colony forming units of *S. mutans* biofilms, with the seed hexane showing bactericidal activity. Microorganisms in biofilms are known to be more resistant to antimicrobial agents than are cells in suspension (planktonic state), and are more complex and similar to the biofilms in the conditions of oral cavity (Lewis, 2001; Bowen, 2002; Marsh, 2003), showing that these results might be of great importance for anticaries studies. However, none of the extracts was as effective in reducing colony forming units as chlorhexidine 0.12%, a clinically proven antimicrobial agent (Marsh, 1992).

Since the other extracts tested displayed no antibacterial activity and the hexane extracts could reduce the viability of *S. mutans* biofilms in time-kill assay, the bioactive compound present in both peel and seed hexane extracts was isolated and identified in our study. Delle Monache et al. (1983) were the first to investigate the genus *Rheedia* (Guttiferae) and its chemical composition. Dos Santos et al. (1999) have isolated the new

polyprenylated benzophenone, denominated 7-epiclusianone. This compound has been reported as having good antimicrobial activity against *Staphylococcus aureus* and phytoacteria (Dos Santos, 1996).

The present study identified 7-epiclusianone as the bioactive compound, with MIC values approximately 10 times lower than those observed for the active hexane extracts, having more complexes in their composition (7-epiclusianone present in a diluted form) and similar to those observed for chlorhexidine. 7-epiclusianone is not a synthetic substance, with its origin exclusively from the nature. This new biological property of 7-epiclusianone is of great relevance in dentistry due to its antibacterial activity against *S. mutans*.

In conclusion, our results showed that the polyprenylated benzophenone 7-epiclusianone, obtained from the *R. brasiliensis* fruit, could be used as an agent to control cariogenic microorganisms and prevent dental caries. However, further studies are needed to investigate the underlying mechanisms of action and anticariogenic potential of 7-epiclusianone.

Acknowledgements

The authors thank FAPESP (#06/56379-4), FINEP (2006) and CNPq (#304803/2005-7 and #131751/2006-9) for financial support. This publication is part of the thesis submitted by the first author to the Faculty of Dentistry of Piracicaba.

References

Ajdic, D., McShan, W.M., McLaughlin, R.E., Savic, G., Chang, J., Carson, M.B., Primeaux, C., Tian, R., Kenton, S., Jia, H., Lin, S., Qian, Y., Li, S., Zhu, H., Najjar, F., Lai, H., White, J., Roe, B.A., Ferretti, J.J., 2002. Genome sequence of *Streptococcus mutans* UA159, a cariogenic dental pathogen. Proc. Natl. Acad. Sci. USA. 99, 14434-14439.

Alves, T.M., Alves, R., Romanha, A.J, Zani, C.L., dos Santos, M.H., Nagem, T.J., 1999. Biological activities of 7-epiclusianone. J. Nat. Prod. 62, 369-371.

Badria, F.A., Zidan, O.A., 2004. Natural products for dental caries prevention. J. Med. Food. 7, 381-384.

Baehni, P.C., Takeuchi, Y., 2003. Anti-plaque agents in the prevention of biofilm-associated oral diseases. Oral diseases. 9, 23-29.

Bakana, P., Claeys, M., Totte, J., Pieters, L.A., Van Hoof, L., Tamba-Vemba, Van den Berghe, D.A., Vlietinck, A.J., 1987. Structure and chemotherapeutical activity of a polyisoprenylated benzophenone from the stem bark of *Garcinia huillensis*. J. Ethnopharmacol. 21, 75-84.

Basso, L.A., da Silva, L.H., Fett-Neto, A.G., de Azevedo W.F. Jr., Moreira Ide, S., Palma, M.S., Calixto, J.B., Astolfi Filho, S., dos Santos, R.R., Soares, M.B., Santos, D.S., 2005. The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tuberculosis, and T-cell mediated diseases--a review. Mem. Inst. Oswaldo Cruz. 100, 475-506.

Belli, W.A., Marquis, R.E., 1991. Adaptation of *Streptococcus mutans* and *Enterococcus hirae* to acid stress in continuous culture. Appl. Environ. Microbiol. 57, 239-246.

Bowen, W.H., 2002. Do we need to be concerned about dental caries in the coming millennium? Crit. Rev. Oral Biol. Med. 13, 126-131.

Campbell, R.J., 1996. South American fruits deserving further attention. In: Janick, J. (Ed.), Progress in new crops. ASHS Press, Arlington, pp. 431-439.

Chatterjee, A., Yasmin, T., Bagchi, D., Stohs, S.J., 2003. The bactericidal effects of *Lactobacillus acidophilus*, garcinol and Protykin compared to clarithromycin, on *Helicobacter pylori*. Mol. Cell. Biochem. 243, 29-35.

Corrêa, M.P., 1978. Dicionário de plantas úteis do Brasil e das exóticas cultivadas. Rio de Janeiro: Ministério da Agricultura, 3, 517-520.

- Delle Monache, G., Delle Monache, F., Bettolo, G.B.M., Lima, R.A., 1983. Chemical investigation of the genus *Rheedia*. II Prenylated xanthenes from *Rheedia gardneriana*. J. Nat. Prod. 46, 655-9.
- Delle Monache, F., Delle Monache, G., Gacs-Baitz, E., 1991. Chemistry of the *Clusia* genus 6. Prenylated benzophenone from *Clusia sandienseis*. Phytochemistry. 30, 703.
- Dos Santos, M.H., 1996. Estudo químico dos frutos de *Rheedia gardneriana* e efeito biológico de seus constituintes. Thesis, Universidade Federal de Viçosa, Minas Gerais, Brazil.
- Dos Santos, M.H., Speziali, N.L., Nagem, T., Oliveira, T.T., 1998. Epiclusianone: a new natural product derivative of bicyclo [3.3.1] nonane-2,4,9-trione. Acta Crystallogr. C54, 1990-1992.
- Dos Santos, M.H., Nagem, T.J., Oliveira, T.T., Braz-Filho, R., 1999. 7-epiclusianona: a nova benzofenona tetraprenilada e outros constituintes químicos dos frutos de *Rheedia gardneriana*. Quim. Nova. 22, 654-660.
- Duarte, S., Koo, H., Bowen, W.H., Hayacibara, M.F., Cury, J.A., Ikegaki, M., Rosalen, P.L., 2003. Effect of a novel type of propolis and its chemical fractions on glucosyltransferases and on growth and adherence of mutans streptococci. Biol. Pharm. Bull. 26, 527-531.
- Duarte, S., Rosalen, P.L., Hayacibara, M.F., Cury, J.A., Bowen, W.H., Marquis, R.E., Rehder, V.L., Sartoratto, A., Ikegaki, M., Koo, H., 2006. The influence of a novel propolis on mutans streptococci biofilms and caries development in rats. Arch. Oral Biol. 51, 15-22.
- Gustafson, K.R., Blunt, J.W., Munro, M.H.G., Fuller, R.W., Mckee, T.C., Cardellina, II J.H., McMahon, J.B., Cragg, G.M., Boyd, M.R., 1992. The guttiferones, HIV-inhibitory benzophenones from *Symphonia globulifera*, *Garcinia livingstonei*, *Garcinia ovalifolia* and *Clusia rosea*. Tetrahedron. 48, 10093-10102.
- Hamada, S., Slade, H.D., 1980. Biology, immunology and cariogenicity of *Streptococcus mutans* and dental caries prevention. J. Dent. Res. 63, 407-411.
- Ito, C., Itoigawa, M., Miyamoto, Y., Onoda, S., Rao, K.S., Mukainaka, T., Tokuda, H., Nishino, H., Furukawa, H., 2003. Polyprenylated benzophenones from *Garcinia assigu* and their potential cancer chemopreventive activities. J. Nat. Prod. 66, 206-209.
- Koo, H., Rosalen, P.L., Cury, J.A., Ambrosano, G.M., Murata, R.M., Yatsuda, R., Ikegaki, M., Alencar, S.M., Park, Y.K., 2000. Effect of a new variety of *Apis mellifera* propolis on mutans streptococci. Curr. Microbiol. 41, 192-196.

- Koo, H., Pearson, S.K., Scott-Anne, K., Abranches, J., Cury, J.A., Rosalen, P.L., Park, Y.K., Marquis, R.E., Bowen, W.H., 2002a. Effects of apigenin and tt-farnesol on glucosyltransferase activity, biofilm viability and caries development in rats. *Oral Microbiol. Immunol.* 17, 337-343.
- Koo, H., Rosalen, P.L., Cury, J.A., Park, Y.K., Bowen, W.H., 2002b. Effects of compounds found in propolis on *Streptococcus mutans* growth and on glucosyltransferase activity. *Antimicrob. Agents Chemother.* 46, 1302-1309.
- Koo, H., Hayacibara, M.F., Schobel, B.D., Cury, J.A., Rosalen, P.L., Park, Y.K., Vacca-Smith, A.M., Bowen, W.H., 2003. Inhibition of *Streptococcus mutans* biofilm accumulation and polysaccharide production by apigenin and tt-farnesol. *J. Antimicrob. Chemother.* 52, 782-789.
- Lemos, J.A., Abranches, J., Burne, R.A., 2005. Responses of cariogenic streptococci to environmental stresses. *Curr. Issues Mol. Biol.* 7, 95-107.
- Lewis, K., 2001. Riddle of biofilm resistance. *Antimicrob. Agents Chemother.* 45, 999-1007.
- Loesche, W.J., 1986. Role of *Streptococcus mutans* in human dental decay. *Microbiol. Rev.* 50, 353-80.
- Marsh, P.D., 1992. Microbiological aspects of the chemical control of plaque and gingivitis. *J. Dent. Res.* 71, 1431-1438.
- Marsh, P.D., 2003. Plaque as a biofilm: pharmacological principles of drug delivery and action in the sub- and supragingival environment. *Oral diseases.* 9, 16-22.
- Morton, J., 1987. Bakupari. In: Morton, J.F., *Fruits of warm climates.* Miami, FL, pp.309-310.
- Newman, D.J., Cragg, G.M., 2007. Natural products as sources of new drugs over the last 25 years. *J. Nat. Prod.* 70, 461-477.
- Paes Leme, A.F., Koo, H., Bellato, C.M., Bedi, G., Cury, J.A., 2006. The role of sucrose in cariogenic dental biofilm formation--new insight. *J. Dent. Res.* 85, 878-87.
- Phillips, I., 1991. A guide to sensitivity testing. *J. Antimicrob. Chemother.* 27, 1-50.
- Piddock, L.J.V., 1990. Techniques used for the determination of antimicrobial resistance and sensitivity in bacteria. *J. Appl. Bacteriol.* 68, 307-318.
- Rios, J.L., Recio, M.C., Villar, A., 1988. Screening methods for natural products with antimicrobial activity: a review of the literature. *J. Ethnopharmacol.* 23, 127-49.

Smith, D.J., 2002. Dental caries vaccines: prospects and concerns. *Crit. Rev. Oral Biol. Med.* 13, 335-349.

Tichy, J., Novak, J., 1998. Extraction, assay, and analysis of antimicrobials from plants with activity against dental pathogens (*Streptococcus* sp.). *J. Altern. Complement. Med.* 4, 39-45.

Yamaguchi, F., Saito, M., Ariga, T., Yoshimura, Y., Nakazawa, H., 2000. Free radical scavenging activity and antiulcer activity of garcinol from *Garcinia indica* fruit rind. *J. Agric. Food Chem.* 48, 2320-2325.

Yatsuda, R., Rosalen, P.L., Cury, J.A., Murata, R.M., Rehder, V.L., Melo, L.V., Koo, H., 2005. Effects of *Mikania* genus plants on growth and cell adherence of mutans streptococci. *J. Ethnopharmacol.* 97, 183-189.




Fig. 1. Chemical structure of 7-epiclusianone, a polyprenylated benzophenone.




Fig. 2. HPLC chromatograms of hexane extracts from *Rheedia brasiliensis* fruit. A – PHE: peel hexane extract; B – SHE: seed hexane extract; 1 – 7-epiclusianone (retention time: 17.961 min in PHE and 17.959 min in SHE).

Table 1. MIC and MBC results from *Rheedia brasiliensis* fruit extracts and 7-epiclusianone.

Microorganism	EXTRACTS (µg/ml)								COMPOUND (µg/ml)	
	Seed hexane		Peel hexane		Peel ethanol		Peel ethyl- acetate		7-epiclusianone	
	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC
<i>S. mutans</i> UA159	12.5-25	50-100	12.5-25	25-50	>800	>800	>800	>800	1.25-2.5	10-20

MIC and MBC values for chlorhexidine (positive control) were 1-2 µg/ml and 8 µg/ml, respectively.




Fig. 3. Results from time-kill study with the hexane extracts and negative (vehicle) and positive (chlorhexidine) controls.

2.2 Capítulo 2:

Effects of 7-epiclusianone on *Streptococcus mutans* and its anticaries activity in rats

L.S.B. Almeida^a, R.M. Murata^a, E.M. Franco^a, M.H. Dos Santos^b, H. Koo^c, P.L. Rosalen^{a,*}

^aDepartment of Physiological Sciences, Faculty of Dentistry of Piracicaba, State University of Campinas, SP, Brazil;

^bLaboratory of Phytochemistry and Medicinal Chemistry, Federal University of Alfenas, MG, Brazil;

^cCenter for Oral Biology and Eastman Department of Dentistry, University of Rochester Medical Center, Rochester, NY, USA.

***Corresponding author:**

Tel.: +551921065313 / Fax.: +551921065218

E-mail address: rosalen@fop.unicamp.br

Abstract

The aim of this study was to evaluate the effects of 7-epiclusianone on virulence factors of *Streptococcus mutans* and its anticaries activity. 7-epiclusianone (7-epi) was obtained from peel hexane extract (PHE) of *Rheedia brasiliensis* fruits and dissolved in a phosphate buffer containing 15% ethanol (vehicle). The influence of 7-epi (at 12.5, 25, 50 and 100 µg/ml) on glucosyltransferase (GTF) B activity was evaluated using the surface-adsorbed enzyme. The effects of 7-epi (at 125 and 250 µg/ml) on *S. mutans* UA159 biofilms were analyzed using glycolytic pH-drop and inhibition of formation assays. PHE (at 500 µg/ml) and 15% ethanol were used as active and vehicle controls, respectively. The animal study used *Wistar* rats, under cariogenic challenge, treated twice daily with 7-epi (250 µg/ml) as well as the positive (250 ppm F) and vehicle controls. 7-epi (100 µg/ml) reduced the activity of GTF B (48% of inhibition). The acids produced by *S. mutans* biofilms were reduced by 7-epi, and the difference was statistically different from vehicle control considering all times evaluated at the higher concentration tested ($p < 0.05$). The compound showed no significant effect on formation and accumulation of biofilms when compared to vehicle control ($p > 0.05$). In the animal study, 7-epi reduced the incidence and severity of smooth-surface and sulcal caries and the total microbiota ($p < 0.05$), but not the *S. mutans*. The caries reduction probably occurred because of the action of 7-epi against virulence factors of *S. mutans*. In conclusion, 7-epi may be used as a new pharmacological agent to prevent and control dental caries; however; further studies are needed to investigate its toxicological effects.

Keywords: 7-epiclusianone, *Streptococcus mutans*, glucosyltransferase B, biofilm, dental caries, animal study.

Introduction

Dental caries is a common infectious disease associated with microorganisms, such as mutans streptococci, capable of forming a complex biofilm on tooth surfaces. This biofilm formation occurs as a three-dimensional consortium of microorganisms functionally organized within an extracellular matrix (Marsh, 2003). Inside the biofilm, mutans streptococci can modify their environment to optimize their growth and metabolism (Davey & O'Toole, 2000).

Streptococcus mutans is considered the bacterium having the most important role in dental caries initiation and development (Loesche, 1986; Van Houte, 1994). In the presence of sucrose, this oral pathogen is capable of producing acids and synthesizing glucans. The acid production can reduce the pH of dental biofilm to low levels, leading to tooth demineralization; the synthesis of glucans occurs by the action of extracellular B, C and D glucosyltransferases (GTFs). GTF B has been considered one of the most important, since it is responsible for the synthesis of insoluble glucans (Yamashita *et al.*, 1993). Synthesis of glucans allows bacteria to attach to dental surfaces and provides the dental biofilm with a stable matrix (Schilling & Bowen, 1992).

These physiological characteristics of *S. mutans*, as well as its ability to survive in acid environments (Quivey *et al.*, 2000) and to respond to acid stress by changing its protein expression (Welin *et al.*, 2004; Svensäter *et al.*, 2000), have been reported in previous studies investigating the virulence factors of *S. mutans*.

Besides the mechanical removal of biofilm and the control of sugar intake, some natural products have been used as antimicrobial agents against virulence factors of *S. mutans* in an attempt to find new pharmacological agents to prevent and control dental caries (Baehni & Takeuchi, 2003). Studies investigating natural compounds as antimicrobial agents against *S. mutans* and other mutans streptococci have shown an interference with virulence factors of such microorganisms and a reduction on caries development *in vivo* (Koo *et al.*, 2002, 2003; Duarte *et al.*, 2006).

In a recent study, the polyprenylated bezophenone 7-epiclusianone was isolated from the fruits of *Rheedia brasiliensis* Planch. & Triana (Syn. *Garcinia brasiliensis* Mart.) (Almeida *et al.*, 2008, *in press*), a plant from Guttiferae family native to the Amazon region

(Corrêa, 1978; Morton, 1987). Its activity against planktonic cells of *S. mutans* was investigated, showing antimicrobial properties (minimum inhibitory concentration of 1.25-2.5 µg/ml) (Almeida *et al.*, 2008, *in press*). However, it is important to evaluate the mechanisms of action of 7-epiclusianone against *S. mutans*, such as its effects on virulence factors, and to verify the anticariogenic potential of such compound. The aim of this study was to investigate the influence of 7-epiclusianone on surface-adsorbed GTF B and on the acidogenicity and formation of *S. mutans* biofilms. We also analyzed the influence of this compound on caries development in rats subjected to a high cariogenic challenge.

Materials and Methods

Plant material

R. brasiliensis is cultivated at the herbarium of the University of Viçosa (latitude 20°45'14" south and longitude 42°52'55" west), Minas Gerais, Brazil (voucher specimen number: VIC2604). 7-epiclusianone [m.p. 92-93 °C (MeOH); $[\alpha]_D^{25} +77$ (c 0.1, CHCl₃)] (Fig. 1) was obtained from the peel (pericarp) hexane extract (PHE) as previously described (Dos Santos *et al.*, 1999; Almeida *et al.*, 2008, *in press*). 7-epiclusianone (purity 99.85%) and PHE were dissolved in a phosphate buffer containing 15% ethanol (v/v – vehicle) just prior to the tests. Different concentrations of 7-epiclusianone (7-epi) were used to test its effect on GTF B activity (12.5 to 100 µg/ml) and for biofilm assays (125 and 250 µg/ml). Biofilm assays also tested PHE at 500 µg/ml and 15% ethanol (v/v) as active and vehicle control, respectively. For the animal study, the highest concentration of 7-epi was used (250 µg/ml) and 250 ppm F and 15% ethanol were used as positive and vehicle control, respectively.

Bacteria

The bacterium strain used for the production of glucosyltransferase B was the *Streptococcus anginosus* KSB8, which harbors the *gtfB* gene. *Streptococcus mutans* UA159 was the oral pathogen used for the biofilm assays and animal study. The cultures were stored at –80 °C in Brain Heart Infusion (BHI) containing 20% glycerol (v/v).

Saliva

In the present study, the hydroxyapatite beads (Macro-Prep Ceramic Hydroxyapatite Type I, 80 μm , Bio-Rad[®], Hercules, CA) and discs (HAP ceramic – calcium hydroxyapatite, 0.5” diameter ceramic – Clarkson Calcium Phosphates, Williamsport, PA) were coated in saliva, which was stimulated (paraffin film) and collected from one donor (Ethics Committee in Research of the School of Dentistry of Piracicaba – State University of Campinas – Protocol No 012/2007). The saliva was clarified by centrifugation (9.500 g, 4 °C, 10 min) and diluted (1:1) in adsorption buffer (50 mM KCl, 1 mM KPO₄, 1 mM CaCl₂, 0.1 mM MgCl₂, pH 6.5), supplemented with the protease inhibitor phenylmethylsulfonyl-fluoride (PMSF) at a final concentration of 1 mmol/l. For GTF assays, the saliva was also supplemented with sodium azide (0.02%, final concentration) (Koo *et al.*, 2000).

Glucosyltransferase (GTF) B activity on surface assay

The GTF B enzymes were purified to near homogeneity by hydroxyapatite column chromatography as described by Venkitaraman *et al.* (1995). GTF activity was measured by the incorporation of [¹⁴C] glucose from labeled sucrose (NEN Research Products, Boston, Mass., USA) into glucans. The GTF B enzyme added to each sample was equivalent to the amount required to incorporate 1-1.5 μmol of glucose over the 4-h reaction. To evaluate the activity of GTF B on surface, we used hydroxyapatite beads coated with clarified whole saliva free of GTF activity in the presence or absence (control) of 7-epi (12.5, 25, 50 and 100 $\mu\text{g/ml}$), as described by Schilling & Bowen (1988). This evaluation was carried out in triplicate in at least three different experiments.

Biofilm assays

For biofilm assays, the saliva-coated hydroxyapatite discs were placed in a vertical position in batch cultures of *S. mutans* UA159, containing an ultrafiltered (Amicon 10 kDa molecular weight cut-off membrane, Millipore Co., MA, USA) tryptone-yeast extract with sucrose (1%, final concentration), at 37 °C, 5% CO₂ (Koo *et al.*, 2003). Biofilms were first grown for 24 h to allow initial formation. At this point and each day,

they were transferred to fresh culture medium (glycolytic pH-drop assay) and also treatments (inhibition of biofilm formation assay) until the fifth day, according to the experiments described below. All assays were done in duplicate on at least three different experiments.

Glycolytic pH-drop

The acid production by *S. mutans* biofilms exposed to the test agents was evaluated by glycolytic pH-drop assay (Belli *et al.*, 1995). 5-days-old biofilms (without daily treatments) were washed in salt solution (50 mM KCl, 1 mM MgCl₂·6H₂O, pH 7.0) and exposed to 7-epi (125 and 250 µg/ml) and active (PHE – 500 µg/ml) and vehicle (15% ethanol) controls for 0, 1, 2 and 3 h. The initial pH (0 h) of the solutions containing biofilms and the test agents was titrated with 0.25 M KOH to a pH just above 7.2. The effects of 7-epi on glycolytic pH-drop were measured in presence of excess glucose, which was added to a final concentration of 1% (v/v) to allow bacteria to produce acids. The pH values were monitored with an Orion pH electrode attached to Orion 290A⁺ pHmeter. The pH values were measured every 1 h and until the third hour.

Inhibition of biofilm formation

To evaluate the effect of the test agents on biofilm formation, 24h-old biofilms (initial formation period) were treated with 7-epi (125 and 250 µg/ml), PHE (500 µg/ml) or vehicle control (15% ethanol) twice a day (10 a.m. and 4 p.m.) until the fifth day of experiment. The biofilms were exposed to the treatments for 1 min, double-dip rinsed in sterile 0.9% NaCl and transferred to fresh culture medium (Koo *et al.*, 2003). At the fifth day, the treated biofilms were removed from discs (ultrasonic bath), serially diluted and plated in Tryptic Soy Agar (TSA). The plates were incubated in 5% CO₂, at 37 °C, for 48 h, and then colony forming units per ml (cfu/ml) were quantified. In addition, an aliquot (1 ml) of the diluted suspension was used for determining the biomass (dry weight).

Animal study

This study was approved by the Ethical Committee on Animal Research at the State University of Campinas – UNICAMP (Protocol No 963-1) and was performed as described elsewhere (Bowen *et al.*, 1988; Koo *et al.*, 2003).

To conduct the experiment, 36 specific pathogen-free female *Wistar* rats, aged 19 days, were purchased from CEMIB/UNICAMP (Campinas, Brazil). Rats were first screened for indigenous mutans streptococci as previously described (Bowen *et al.*, 1988). When aged 20, 21, 22 and 23 days, they were infected with bacterial suspensions obtained from 3-days-old *S. mutans* biofilms formed on glass microscope slides (Koo *et al.*, 2003).

At age 25 days, the animals were randomly divided into three groups, according to the treatment (12 animals each group): 1) 7-epi 250 µg/ml; 2) 250 ppm F (positive control) - concentration chosen based on data from previous studies (Koo *et al.*, 2003; Koo *et al.*, 2005); 3) 15% ethanol (v/v) (vehicle control for all groups). Their molars were treated using a camel hair brush twice daily (9 a.m. and 2 p.m.) until the last day of experiment (5 weeks). The rats, which were placed in individual cages, were provided with cariogenic diet 2000 (Keyes, 1959) and 5% sucrose water *ad libitum*. The animals were weighed weekly, also observing their physical appearance daily.

At the end of the 5-week experimental period, the rats were killed by CO₂ asphyxiation. The lower left jaw was aseptically dissected, suspended in 5.0 ml of a sterile 0.9% NaCl solution and sonicated (six 10-s pulses at 5-s intervals, at 40 watts, Vibra Cell, Sonics & Material Inc.). Aliquots (50 µl) of the suspensions were plated on blood agar and on Mitis Salivarius Agar plus bacitracin (Sigma[®]), using a Spiral Plater (Whitley Automatic Spiral Plater), to determine, respectively, the number of total microorganisms and *S. mutans* populations. The smooth-surface and sulcal caries and their severities were evaluated according to Larson's modification of Keyes' system (Larson, 1981). The determination of caries score was blinded and performed by one calibrated examiner.

Statistical analyses

The data were subjected to ANOVA and Tukey-Kramer test to adjust for multiple comparisons, using JMP version 3.1 software for statistical visualization. The level of significance was set at 5%.

Results

GTF B activity on surface

The effects of 7-epi on glucan synthesis are shown in Table 1. In the highest concentration tested, the test compound reduced the activity of GTF B on surface with approximately 50% of inhibition of activity. The activity of the enzyme was diminished when the doses were increased (Table 1).

Biofilm assays

Glycolytic pH drop

The acid production by *S. mutans* biofilms was affected by 7-epi, as well as by its origin fraction (PHE 500 µg/ml), in both concentrations tested (125 and 250 µg/ml). After 3 h exposure to test agents, biofilms had pH values higher than 5.5. In absence of 7-epi, the final pH values were lower than 5.0 after 3 h (4.7 for vehicle control). 7-epi at 250 µg/ml reduced the acid production by *S. mutans* biofilms and was statistically different from vehicle control in all hours tested ($p < 0.05$) (Fig. 2). 7-epi at 125 µg/ml and PHE at 500 µg/ml inhibited the acid production after the second hour when compared to the vehicle ($p < 0.05$) and they were not statistically different from 7-epi at 250 µg/ml ($p > 0.05$).

Inhibition of biofilm formation

The biofilms treated with 7-epi at 250 µg/ml and PHE at 500 µg/ml showed slightly lower numbers of recoverable viable cells when compared to the vehicle control, but the difference was not statistically significant (Table 2, $p > 0.05$). All agents could not reduce statistically the accumulation of biomass (dry weight) of *S. mutans* biofilms at the concentrations tested (Table 2, $p > 0.05$), although we observed a reduction with 7-epi at 250 µg/ml.

Animal study

In the present study, the animals maintained a good health during all the experiment. The weight gain of animals was not statistically significant among 7-epi,

positive (250 ppm F) and vehicle control (15% ethanol) groups ($p>0.05$) (data not shown). The effects of the treatments on the incidence and severity of smooth-surface caries and sulcal caries are shown in Table 4. 7-epi reduced the total caries of smooth-surface and total sulcal caries and the severity of caries in dentin when compared to the vehicle control ($p<0.05$), but the positive control (250 ppm F) showed better results for all parameters related to the incidence and severity of caries than 7-epi. The total microbiota was reduced by treatment with 7-epi and 250 ppm F when compared to the vehicle ($p<0.05$) (Table 3). However, there was no difference regarding the number and percentage of *S. mutans* among the groups tested ($p>0.05$) (Table 3).

Discussion

The high incidence of dental caries in some populations of the world and all damages caused by this infectious disease have required new strategies to its prevention and control (Antunes *et al.*, 2004). Studies on compounds isolated from natural products have reported antibacterial activity against mutans streptococci, also reducing caries in animals (Koo *et al.*, 2003a; Duarte *et al.*, 2006).

The present study was aimed at investigating the polyprenylated benzophenone 7-epiclusianone (7-epi), focusing on its antimicrobial activity and anticaries effect. This compound, obtained from *Rheedia brasiliensis* fruits (Guttiferae family), showed actions against important virulence traits of *Streptococcus mutans*, by reducing its ability to synthesize insoluble glucans and produce acids, and also reduced the incidence of caries in rats.

The synthesis of insoluble glucans (α 1,3-linked glucans) by GTF B, specially surface-adsorbed enzyme, facilitates the adherence of *S. mutans* and contributes to the formation of biofilm matrix (Schilling & Bowen, 1992). This matrix makes it difficult for antimicrobial agents to act against biofilms (Koo *et al.*, 2002; Wunder & Bowen, 1999). Even at low concentrations (12.5-100 μ g/ml), 7-epi could reduce the activity of GTF B, probably affecting the *S. mutans* adherence as a consequence. Previous studies focusing on effects of other clinical agents, including chlorhexidine (0.12%) and fluoride (250 ppm), on

GTF B showed negligible or moderate inhibitory results (Wunder & Bowen, 1999; Koo *et al.*, 2003a).

The concentrations used for 7-epi (125 and 250 µg/ml) to evaluate its activity against *S. mutans* biofilms were approximately 100 times higher than the MIC values obtained for the compound tested, as previously described by Marsh (1992) concerning other antimicrobial agents. When compared to those reported in previous studies on natural products (Koo *et al.*, 2003a, 2003b; Duarte *et al.*, 2006), the 7-epi concentrations tested were considered low and were chosen just to avoid problems with solubility (7-epi is a weak acid with non-polar characteristics) and toxicological effects.

In the present study, 7-epi was observed to interfere with acids produced by *S. mutans* biofilms as well as to maintain pH at levels higher than those (5.0-5.5) known to cause enamel demineralization. This compound at concentrations of 125 µg/ml and 250 µg/ml reduced acid production starting at the 2-hour period when compared to the vehicle ($p < 0.05$), using the glycolytic pH-drop test. This reduction in acid production might be related to the ability of 7-epi to inhibit the F-ATPase enzyme, which allows bacteria to survive in acid environments, or even to the inhibition of glycolytic enzymes by 7-epi, suggesting that further studies are needed to investigate such hypothesis. Since biofilm acts as a barrier to antibiotic diffusion (Stewart, 1996), 7-epi was observed to have good activity against acid production by *S. mutans*.

However, this compound could not reduce the accumulation and formation of *S. mutans* biofilms treated twice daily, suggesting that the action of 7-epi, at the concentrations tested, might be related to virulence factors of *S. mutans* (activity of GTF B and acid production) and not to its bactericidal effect. Similar results were found in the literature concerning the action of natural products against the virulence of mutans streptococci as test agents showed no effect on the viability of bacterial biofilms (Duarte *et al.*, 2006).

7-epi was able to reduce the incidence and severity of caries in rats submitted to cariogenic challenges, without a reduction in *S. mutans* when compared to the vehicle control ($p > 0.05$), confirming the results obtained with the *in vitro* tests. The group treated with 250 ppm F presented lower incidence and severity of caries than 7-epi and showed the

same pattern for total microbiota and *S. mutans* as 7-epi. The best results for fluoride, the most effective anticaries agent (Clarkson, 2000), might be attributed to its additional physicochemical actions (Hamilton, 1990). Similar data were observed in a previous study evaluating the effects of fluoride and natural products on dental caries in rats (Koo *et al.*, 2003a).

Some anticaries agents, when compared to some bioactive compounds, were observed to be more efficient in preventing dental caries in rats (Koo *et al.*, 2003); however, it is well known that there are differences among drugs concerning their mechanism of action as well as their substantivity (Dawes & Ten Cate, 1990; Jones, 1997).

Based on the *in vitro* and *in vivo* results obtained in the present study, it could be suggested that the anticaries activity of 7-epi might be related to a reduction on *S. mutans* virulence, and not to its bactericidal activity. Substances that act on *S. mutans* virulence factors could be used to control dental caries or even to enhance the anticariogenic effect of other recognized agents, such as fluoride (Koo *et al.*, 2003a; Koo *et al.*, 2005).

In conclusion, 7-epi could be considered a promising agent to prevent and control dental caries. Further studies are needed to investigate its activity against multispecies biofilms as well as its toxicological effects.

Acknowledgements

The authors thank FAPESP (#06/56379-4) and CNPq (#304803/2005-7 and #131751/2006-9) for financial support. We are grateful to José Carlos Gregorio for technical assistance. This publication is part of the thesis submitted by the first author to the Faculty of Dentistry of Piracicaba.

References

Almeida LSB, Murata RM, Yatsuda R, Santos MH, Nagem TJ, Alencar SM, Koo H, Rosalen PL. Antimicrobial activity of *Rheedia brasiliensis* and 7-epiclusianone against *Streptococcus mutans*. *Phytomedicine*, *in press* 2008.

Antunes JFL, Narvai PC, Nugent ZJ. Measuring inequalities in the distribution of dental caries. *Community Dent Oral Epidemiol*. 2004; 32: 41-48.

Baehni PC, Takeuchi Y. Anti-plaque agents in the prevention of biofilm-associated oral diseases. *Oral diseases*. 2003; 9: 23-29.

Belli WA, Buckley DH, Marquis RE. Weak acid effects and fluoride inhibition of glycolysis by *Streptococcus mutans* GS-5. *Can J Microbiol*. 1995 Sep; 41(9): 785-91.

Bowen WH, Madison KM, Pearson SK. Influence of desalivation in rats on incidence of caries in intact cagemates. *J Dent Res*. 1988 Oct; 67(10): 1316-8.

Clarkson JJ. International collaborative research on fluoride . *J Dent Res*. 2000; 79: 893-904.

Corrêa, M.P., 1978. Dicionário de Plantas Úteis do Brasil e das Exóticas Cultivadas. 3, 517-520. Ministério da Agricultura, Imprensa Nacional, Rio de Janeiro.

Davey ME, O'toole GA. Microbial biofilms: from ecology to molecular genetics. *Microbiol Mol Biol Rev*. 2000 Dec; 64(4): 847-67.

Dawes C, Ten Cate JM. International symposium on fluorides: mechanisms of action and recommendations for use. *J Dent Res*. 1990; 69: 505-836.

Dos Santos MH, Speziali NL, Nagem T, Oliveira TT. Epiclusianone: a new natural product derivative of bicyclo [3.3.1] nonane-2,4,9-trione. *Acta Crystallogr*. 1998; C54: 1990-1992.

Dos Santos MH, Nagem TJ, Oliveira TT, Braz-Filho R. 7-epiclusianona: a nova benzofenona tetraprenilada e outros constituintes químicos dos frutos de *Rheedia gardneriana*. *Quim Nova*. 1999; 22: 654-660.

Duarte S, Rosalen PL, Hayacibara MF, Cury JA, Bowen WH, Marquis RE, Rehder VL, Sartoratto A, Ikegaki M, Koo H. The influence of a novel propolis on mutans streptococci biofilms and caries development in rats. *Arch Oral Biol*. 2006; 51: 15-22.

Hamilton IR. Biochemical effects of fluoride on oral bacteria. *J Dent Res*. 1990; 69: 668-71.

Jones CG. Chlorhexidine: is it still the gold standard? *Periodontol 2000*. 1997; 15: 55-62.

Keyes PH. Dental caries in the molar teeth of rats. I. Distribution of lesions induced by high carbohydrate low-fat diets. *J Dent Res.* 1958 Nov-Dec; 37(6): 1077-87.

Koo H, Vacca-Smith AM, Bowen WH, Rosalen PL, Cury JA, Park YK. Effects of *Apis mellifera* propolis on the activities of streptococcal glucosyltransferases in solution and adsorbed onto saliva-coated hydroxyapatite. *Caries Res.* 2000; 34: 418-426.

Koo H, Pearson SK, Scott-Anne K, Abranches J, Cury JA, Rosalen PL, Park YK, Marquis RE, Bowen WH. Effects of apigenin and tt-farnesol on glucosyltransferase activity, biofilm viability and caries development in rats. *Oral Microbiol Immunol.* 2003a Dec; 17(6): 337-43.

Koo H, Hayacibara MF, Schobel BD, Cury JA, Rosalen PL, Park YK, Vacca-Smith AM, Bowen WH. Inhibition of *Streptococcus mutans* biofilm accumulation and polysaccharide production by apigenin and tt-farnesol. *J Antimicrob Chemother.* 2003b; 52: 782-789.

Koo H, Schobel B, Scott-Anne K, Watson G, Bowen WH, Cury JA, *et al.*. Apigenin and tt-farnesol with fluoride on *S. mutans* biofilms and dental caries. *J Dent Res.* 2005 Nov; 84(11): 1016-1020.

Larson RM. Merits and modifications of scoring rat dental caries by Keyes' method. *In: Tanzer JM. Microbiology Abstracts (special suppl.), IRL Press, Animal Models in Cariology, Washington, p.195-203, 1981.*

Loesche WJ. Role of *Streptococcus mutans* in human dental decay. *Microbiol Rev.* 1986; 50: 353-80.

Marsh PD. Microbiological aspects of the chemical control of plaque and gingivitis. *J Dent Res.* 1992; 71: 1431-1438.

Marsh PD. Plaque as a biofilm: pharmacological principles of drug delivery and action in the sub- and supragingival environment. *Oral diseases.* 2003; 9: 16-22.

Morton, J., 1987. Bakupari. *In: Morton, J.F., Fruits of warm climates. Miami, FL, pp.309-310.*

Quivey RG Jr, Faustoferri R, Monakan K, Marquis R. (2000). Shifts in membrane fatty acid profiles associated with acid adaptation of *Streptococcus mutans*. *FEMS Microbiol Lett.* 2000; 189: 89-92.

Schilling KM, Bowen WH. The activity of glucosyltransferases adsorbed onto saliva-coated hydroxyapatite. *J Dent Res.* 1988; 67: 2-8.

Schilling KM, Bowen WH. Glucans synthesized in situ in experimental salivary pellicle function as specific binding sites for *Streptococcus mutans*. *Infect Immun*. 1992; 60: 284-295.

Stewart PS. Theoretical aspects of antibiotic diffusion into microbial biofilms. *Antimicrob Agents Chemother*. 1996 Nov; 40(11): 2517-2522.

Svensäter G, Welin J, Wilkins JC, Beighton D, Hamilton IR. Protein expression by planktonic and biofilm cells of *Streptococcus mutans*. *FEMS Microbiol Lett*. 2001 Nov 27; 205(1): 139-46.

Van Houte J. Role of micro-organisms in caries etiology. *J Dent Res*. 1994 Mar; 73(3): 672-81.

Venkitaraman AR, Vacca-Smith AM, Kopec LK, Bowen WH. Characterization of glucosyltransferase B, GtfC, and GtfD in solution and on the surface of hydroxyapatite. *J Dent Res*. 1995; 74: 1695–1701.

Welin J, Wilkins JC, Beighton D, Svensäter G. Protein expression by *Streptococcus mutans* during initial stage of biofilm formation. *Appl Environ Microbiol*. 2004 Jun; 70(6): 3736-41.

Wunder D, Bowen WH. Action of agents on glucosyltransferases from *Streptococcus mutans* in solution and adsorbed to experimental pellicle. *Arch Oral Biol*. 1999 Mar; 44(3): 203-14.

Yamashita Y, Bowen WH, Burne RA, Kuramitsu HK (1993). Role of the *Streptococcus mutans* gtf genes in caries induction in the specific-pathogen-free rat model. *Infect Immun*. 1993; 61: 3811–3817.




Fig. 1. Chemical structure of 7-epiclusianone, a polyprenylated benzophenone obtained from *Rheedia brasiliensis*.

Table 1. Effects of 7-epiclusianone (7-epi) on the activity of GTF B on surface.

Concentration of 7-epi ($\mu\text{g/ml}$)	GTF B (% of inhibition)
100	48.0 ± 1.8
50	33.4 ± 4.7
25	26.6 ± 4.7
12.5	9.2 ± 6.2

The percentage of inhibition was calculated considering the vehicle control (15% ethanol) as 100% glucosyltransferase activity (n=9).




Fig. 2. Influence of 7-epiclusianone (7-epi) and its active (peel hexane extract – PHE) and vehicle (15% ethanol) controls on glycolytic pH-drop in *S. mutans* UA159 biofilms.

* Indicates a statistically significant difference among vehicle control (15% ethanol) and each treatment ($p < 0.05$) ($n=6$).

Table 2. Influence of test agents on *Streptococcus mutans* UA159 biofilms formation (dry-weight and viability): means (\pm SD).

Treatments	Dry-weight (mg)	cfu/ml ($\times 10^6$)
Vehicle	6.5 \pm 1.9	1.5 \pm 0.7
7-epi 250 μ g/ml	5.2 \pm 1.8	1.1 \pm 0.3
7-epi 125 μ g/ml	6.2 \pm 1.7	1.5 \pm 0.4
PHE 500 μ g/ml	6.9 \pm 2.0	0.9 \pm 0.4

No statistical differences were found for dry-weight (biomass) and cfu/ml among the treatments ($p > 0.05$, ANOVA, comparison for all pairs using Tukey-Kramer HSD) ($n=6$).

Table 3. Effects of 7-epiclusianone (7-epi) and positive (250 ppm F) and vehicle (15% ethanol) controls after five-week experiment on oral microbiota in rats: means (\pm SD).

Treatment	Total microorganisms ($\times 10^4$ cfu/ml)	<i>Streptococcus mutans</i> UA159 ($\times 10^4$ cfu/ml)	<i>Streptococcus mutans</i> UA159 (%)
Vehicle	3.6 (1.7) ^a	2.6 (1.9) ^a	63.8 (21.3) ^a
7-epi 250 μ g/ml	1.8 (0.7) ^b	1.2 (0.5) ^a	66.7 (17.2) ^a
250 ppm F	1.9 (0.5) ^b	1.6 (0.3) ^a	62.4 (14.1) ^a

Values followed by the same letters (vertical) are not significantly different from each other ($p > 0.05$) (n=12). ANOVA, comparison for all pairs using Tukey-Kramer HSD.

Table 4. Effects of 7-epiclusianone (7-epi) and respective controls on caries development (smooth-surface and sulcal caries) and severity (Ds, dentin exposed; Dm, 3/4 of the dentin affected; Dx, dentin loss) in rats, after five-week experiment: means (\pm SD) of Keyes' scores modified by Larson.

GROUP	Smooth-Surface				Sulcal			
	TOTAL	Severity			TOTAL	Severity		
		Ds	Dm	Dx		Ds	Dm	Dx
Vehicle	78.6 ^a (5.8)	44.8 ^a (8.1)	19.9 ^a (7.0)	7.0 ^a (7.2)	47.1 ^a (4.0)	38.9 ^a (3.0)	30.5 ^a (5.3)	22.6 ^a (5.4)
7-epi 250 μ g/ml	63.9 ^b (6.7)	25.7 ^b (8.1)	3.4 ^b (5.0)	2.1 ^b (3.6)	40.6 ^b (5.0)	25.2 ^b (5.4)	14.9 ^b (5.4)	5.4 ^b (4.7)
250 ppm F	34.8 ^c (4.1)	22.8 ^b (6.7)	0.5 ^b (0.8)	0.0 ^b (0.0)	28.6 ^c (3.3)	16.1 ^c (3.4)	2.6 ^c (1.6)	0.4 ^c (0.7)

Values followed by the same letters (vertical) are not significantly different from each other ($p > 0.05$) (n=12). ANOVA, comparison for all pairs using Tukey-Kramer HSD.

3 Conclusões

No presente estudo, concluiu-se que a 7-epiclusianona extraída da *Rheedia brasiliensis* foi capaz de atuar sobre fatores de virulência do *Streptococcus mutans* e de reduzir cárie dental em modelo animal, sugerindo que este composto possa ser um possível adjunto terapêutico no controle da cárie dental. Estudos toxicológicos são necessários para que o uso da 7-epiclusianona continue sendo considerado.

4 Referências*

Almeida LSB, Murata RM, Santos MH, Koo H, Rosalen PL. Avaliação antimicrobiana da *Rhedia brasiliensis* sobre *Streptococcus mutans* em modelos planctônico e de biofilme. *Braz Oral Res.* 2005; 19 Suppl: p.97.

Alves TM, Alves R, Romanha AJ, Zani CL, dos Santos MH, Nagem TJ. Biological activities of 7-epiclusianone. *J Nat Prod.* 1999 Feb; 62(2): 369-71.

Baehni PC, Takeuchi Y. Anti-plaque agents in the prevention of biofilm-associated oral diseases. *Oral diseases* 2003; 9 (Suppl. I): 23-29.

Bakana P, Claeys M, Totte J, Pieters LA, van Hoof L, Tamba-Vemba *et al.* Structure and chemotherapeutical activity of a polyisoprenylated benzophenone from the stem bark of *Garcinia huillensis*. *J Ethnopharmacol.* 1987; 21(1): 75-84.

Belli WA, Marquis RE. Adaptation of *Streptococcus mutans* and *Enterococcus hirae* to acid stress in continuous culture. *Appl Environ Microbiol.* 1991 Apr; 57(4): 239-246.

Bowen WH. Do we need to be concerned about dental caries in the coming millennium? *Crit Rev Oral Biol Med.* 2002; 13: 126-131.

Bowden, GH. Microbiology of root surface caries in humans. *J Dent Res.* 1990 May; 69(5): 1205-10.

Braz-Filho R. Brazilian phytochemical diversity: bioorganic compounds produced by secondary metabolism as a source of new scientific development, varied industrial applications and to enhance human health and the quality of life. *Pure Appl Chem.* 1999; 71(9): 1663-1672.

Burne RA, Quivey RG Jr, Marquis RE. Physiologic homeostasis and stress responses in oral biofilms. *Methods Enzymol.* 1999; 310: 441-60.

Chatterjee A, Yasmin T, Bagchi D, Stohs SJ. The bactericidal effects of *Lactobacillus acidophilus*, garcinol and Protykin® compared to clarithromycin, on *Helicobacter pylori*. *Mol Cell Biochem.* 2003; 243: 29-35.

Corrêa, M.P., 1978. Dicionário de Plantas Úteis do Brasil e das Exóticas Cultivadas. 3, 517-520. Ministério da Agricultura, Imprensa Nacional, Rio de Janeiro.

* De acordo com a norma da FOP/Unicamp, baseada no modelo de Vancouver. Abreviatura dos periódicos em conformidade com o Medline.

- Cruz AJ, Lemos VS, dos Santos MH, Nagem TJ, Cortes SF. Vascular effects of 7-epiclusianone, a prenylated benzophenone from *Rheedia gardneriana*, on the rat aorta. *Phytomedicine*. 2006 Jun;13(6):442-5. Epub 2005 Sep 16.
- Davey ME, O'toole GA. Microbial biofilms: from ecology to molecular genetics. *Microbiol Mol Biol Rev*. 2000 Dec; 64(4): 847-67.
- Delle Monache G, Delle Monache F, Bettolo GBM, Lima RA. Chemical investigation of the genus *Rheedia*. II Prenylated xanthenes from *Rheedia-gardneriana*. *J Nat Prod*. 1983 Sep-Oct;46(5):655-9.
- Dharmaratne HRW, Piyasena KGNP, Tennakoon SB. A geranylated biphenyl derivative from *Garcinia mangostana*. *Nat Prod Res*. 2005 Apr; 19(3): 239-43.
- Dos Santos MH. Estudo químico dos frutos de *Rheedia gardneriana* e efeito biológico de seus constituintes [dissertação]. Viçosa: Universidade Federal de Viçosa; 1996.
- Dos Santos MH, Nagem TJ, Oliveira TT, Braz-Filho R. 7-epiclusianona: a nova benzofenona tetraprenilada e outros constituintes químicos dos frutos de *Rheedia gardneriana*. *Quim Nova* 1999; 22(5): 654-60.
- Duarte S, Koo H, Bowen WH, Hayacibara MF, Cury JA, Ikegaki M *et al*. Effect of a novel type of propolis and its chemical fractions on glucosyltransferases and on growth and adherence of mutans streptococci. *Biol Pharm Bull*. 2003 Apr; 26(4): 527-31.
- Duarte S, Rosalen PL, Hayacibara MF, Cury JA, Bowen WH, Marquis RE, Rehder VL, Sartoratto A, Ikegaki M, Koo H. The influence of a novel propolis on mutans streptococci biofilms and caries development in rats. *Arch Oral Biol*. 2006; 51: 15-22.
- Gustafson KR, Blunt JW, Munro MHG, Fuller RW, Mckee TC, Cardellina II JH *et al*. The guttiferones, HIV-inhibitory benzophenones from *Symphonia globulifera*, *Garcinia livingstonei*, *Garcinia ovalifolia* and *Clusia rosea*. *Tetrahedron* 1992; 48: 10093-102.
- Hamada S, Slade HD. Biology, immunology and cariogenicity of *Streptococcus mutans* and dental caries prevention. *J Dent Res*. 1980; 63: 407-411.
- Hussain RA, Owegby AG, Parimoo P, Waterman PG. Kolanone, a novel polyisoprenylated benzophenone with antimicrobial properties from the fruit of *Garcinia kola*. *Planta Med*. 1982 Feb; 44(2): 78-81.
- Ito C, Itoigawa M, Miyamoto Y, Onoda S, Rao KS, Mukainaka T *et al*. Polyprenylated benzophenones from *Garcinia assigu* and their potential cancer chemopreventive activities. *J Nat Prod*. 2003; 66(2): 206-209.

- Iinuma M, Tosa H, Tanaka T, Kanamaru S, Asai F, Kobayashi Y *et al.* Antibacterial activity of some *Garcinia* benzophenone derivatives against methicillin-resistant *Staphylococcus aureus*. *Biol Pharm Bull.* 1996; 19(2): 311-314.
- Koo H, Gomes BP, Rosalen PL, Ambrosano GM, Park YK, Cury JA. In vitro antimicrobial activity of propolis and *Arnica montana* against oral pathogens. *Arch Oral Biol.* 2000 Feb; 45(2): 141-8.
- Loesche WJ. Role of *Streptococcus mutans* in human dental decay. *Microbiol Rev.* 1986 Dec; 50(4): 353-80.
- Marquis RE, Phan TE, Buckner T, Sheng J, Bladeck JD. Physiologic actions of zinc related to inhibition of alkali and acid production by oral streptococci in suspensions and biofilms. *Oral Microbiol. Immunol.* 2004; 19, 31-38
- Marsh PD. Plaque as a biofilm: pharmacological principles of drug delivery and action in the sub- and supragingival environment. *Oral diseases.* 2003; 9: 16-22.
- Morton J. Bakupari. In: *Fruits of warm climates.* Julia F. Morton. Miami,FL: 1987, p.309-310. [Acesso 2007 Dez 18]. Disponível em: http://www.hort.purdue.edu/newcrop/morton/bakupari_ars.html.
- Murata RM, Rosalen PL, Koo H, Santos MH, Alencar SM, Cury JA, *et al.*, inventors; University of São Paulo, State University of Campinas, University of Rochester, assignee. Oral compositions and use thereof for isolated compound from *Rheedia brasiliensis*. Brazil patent BR INPI/SP084864. 2006 August 02.
- Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. *J Nat Prod.* 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
- Piccinelli AL, Rubio OC, Chica MB, Mahmood N, Pagano B, Pavone M, *et al.* Structural revision of clusianone and 7-epi-clusianone and HIV-activity of polyprenylated benzophenones. *Tetrahedron* 2005; 61: 8206-8211.
- Rickard AH, Gilbert P, High NJ, Kolenbrander PE, Handley PS. Bacterial coaggregation: an integral process in the development of multi-species biofilms. *Trends Microbiol.* 2003 Feb;11(2):94-100.
- Rubio OC, Cuellar AC, Rojas N, Castro HV, Rastrelli L, Aquino R. A polyisoprenylated benzophenone from cuban propolis. *J Nat Prod.* 1999; 62: 1013-1015.
- Rubio OC, Padron A, Castro HV, Pizza C, Rastrelli L. Aristophenes A and B. A new tautomeric pair of polyisoprenylated benzophenones from *Garcinia aristata*. *J. Nat. Prod.* 2001; 64, 973-975.

Tichy J, Novak J. Extraction, assay, and analysis of antimicrobials from plants with activity against dental pathogens (*Streptococcus* sp.). *J Altern Complement Med*. 1998; 4(1): 39-45.

Tinanoff N, Kanellis MJ, Vargas CM. Current understanding of the epidemiology, mechanism and prevention dental caries in preschool children. *Pediatr Dent*. 2002; 24: 543-51.

Weng JR, Tsao LT, Wang JP, Wu RR, Lin CN. Anti-inflammatory phloroglucinols and terpenoids from *Garcinia subelliptica*. *J Nat Prod*. 2004; 67:1796-99.

Wunder D, Bowen WH. Action of agents on glucosyltransferases from *Streptococcus mutans* in solution and adsorbed to experimental pellicle. *Arch Oral Biol*. 1999 Mar; 44(3): 203-14.

Yamaguchi F, Saito M, Ariga T, Yoshimura Y, Nakazawa. Free radical scavenging activity and antiulcer activity of garcinol from *Garcinia indica* fruit rind. *J Agric Food Chem*. 2000; 48: 2320-2325.

Yamashita Y, Bowen WH, Burne RA, Kuramitsu HK (1993). Role of the *Streptococcus mutans* *gtf* genes in caries induction in the specific-pathogen-free rat model. *Infect Immun*. 1993; 61: 3811–3817.


5 Apêndice

Desenhos esquemáticos dos métodos de obtenção dos extratos e da 7-epiclusianona a partir do fruto da *Rheedia brasiliensis* (bacupari).

➤ Obtenção dos extratos:



➤ Obtenção da 7-epiclusianona:



6 Anexos

6.1 Anexo 1: Resolução do formato alternativo para defesa da dissertação de mestrado.

INFORMAÇÃO CCPG/002/06

Tendo em vista a necessidade de revisão da regulamentação das normas sobre o formato e a impressão das dissertações de mestrado e teses de doutorado e com base no entendimento exarado no Parecer PG nº 1985/96, que trata da possibilidade do formato alternativo ao já estabelecido, a CCPG resolve:

Artigo 1º - O formato padrão das dissertações e teses de mestrado e doutorado da UNICAMP deverão obrigatoriamente conter:

- I. Capa com formato único ou em formato alternativo que deverá conter informações relativas ao nível (mestrado ou doutorado) e à Unidade de defesa, fazendo referência à Universidade Estadual de Campinas, sendo o projeto gráfico das capas definido pela PRPG.
- II. Primeira folha interna dando visibilidade à Universidade, a Unidade de defesa, ao nome do autor, ao título do trabalho, ao número de volumes (quando houver mais de um), ao nível (mestrado ou doutorado) a área de concentração, ao nome do orientador e co-orientador, ao local (cidade) e ao ano de depósito. No seu verso deve constar a ficha catalográfica.
- III. Folha de aprovação, dando visibilidade à Comissão Julgadora com as respectivas assinaturas.
- IV. Resumo em português e em inglês (ambos com no máximo 500 palavras).
- V. Sumário.
- VI. Corpo da dissertação ou tese dividido em tópicos estruturados de modo característico à área de conhecimento.
- VII. Referências, formatadas segundo normas de referenciamento definidas pela CPG da Unidade ou por critério do orientador.
- VIII. Todas as páginas deverão, obrigatoriamente, ser numeradas, inclusive páginas iniciais, divisões de capítulos, encartes, anexos, etc.. As páginas iniciais poderão ser numeradas utilizando-se algarismos romanos em sua forma minúscula.
- IX. Todas as páginas com numeração "ímpar" serão impressas como "frente" e todas as páginas com numeração "par" serão impressas como "verso".

§ 1º - A critério do autor e do orientador poderão ser incluídos dedicatória, agradecimento, epígrafe, lista de ilustrações, tabelas, abreviaturas e siglas, símbolos, glossário, apêndice, anexos.

§ 2º - A dissertação ou tese deverá ser apresentada na língua portuguesa, com exceção da possibilidade permitida no artigo 2º desta Informação.

§ 3º - As dissertações e teses cujo conteúdo versar sobre pesquisa envolvendo seres humanos, animais ou biossegurança, deverão apresentar anexos os respectivos documentos de aprovação.

Artigo 2º - A critério do orientador e com aprovação da CPG da Unidade, os capítulos e os apêndices poderão conter cópias de artigos de autoria ou de co-autoria do candidato, já publicados ou submetidos para publicação em revistas científicas ou anais de congressos sujeitos a arbitragem, escritos no idioma exigido pelo veículo de divulgação.

§ único - O orientador e o candidato deverão verificar junto às editoras a possibilidade de inclusão dos artigos na dissertação ou tese, em atendimento à legislação que rege o direito autoral, obtendo, se necessária, a competente autorização, deverão assinar declaração de que não estão infringindo o direito autoral transferido a editora.

Artigo 3º - Dependendo da área do conhecimento, a critério do orientador e com aprovação da CPG da Unidade, a dissertação ou tese poderá ser apresentada em formato alternativo, desde que observados os incisos I, II, III, IV, V e VII do artigo 1º.

Artigo 4º - Para impressão, na gráfica da Unicamp, dos exemplares definitivos de dissertações e teses defendidas, deverão ser adotados os seguintes procedimentos:

§ 1º - A solicitação para impressão dos exemplares de dissertações e teses poderá ser encaminhada à gráfica da Unicamp pelas Unidades, que se responsabilizarão pelo pagamento correspondente.

§ 2º - Um original da dissertação ou tese, em versão definitiva, impresso em folha tamanho carta, em uma só face, deve ser encaminhado à gráfica da Unicamp acompanhado do formulário "Requisição de Serviços Gráficos", onde conste o número de exemplares solicitados.

§ 3º - A gráfica da Unicamp imprimirá os exemplares solicitados com capa padrão. Os exemplares solicitados serão encaminhados à Unidade em, no máximo, cinco dias úteis.

§ 4º - No formulário "Requisição de Serviços Gráficos" deverão estar indicadas as páginas cuja reprodução deva ser feita no padrão "cores" ou "foto", ficando entendido que as demais páginas devam ser reproduzidas no padrão preto/branco comum.

§ 5º - As dissertações e teses serão reproduzidas no padrão frente e verso, exceção feita às páginas iniciais e divisões de capítulos; dissertações e teses com até 100 páginas serão reproduzidas no padrão apenas frente, exceção feita à página que contém a ficha catalográfica.

§ 6º - As páginas fornecidas para inserção deverão ser impressas em sua forma definitiva, ou seja, apenas frente ou frente/verso.

§ 7º - O custo, em reais, de cada exemplar produzido pela gráfica será definido pela Administração Superior da Universidade.

Artigo 5º - É obrigatória a entrega de dois exemplares para homologação.

Artigo 6º - Esta Informação entrará em vigor na data de sua publicação, ficando revogadas as disposições em contrário, principalmente as Informações CCPG 001 e 002/98 e CCPG/001/00.

Campinas, 13 de setembro de 2006

Profa. Dra. Teresa Dib Zambon Atvars
Presidente
Comissão Central de Pós-Graduação

6.2 Anexo 2: Certificado do Comitê de Ética em Pesquisa.

COMITÊ DE ÉTICA EM PESQUISA
FACULDADE DE ODONTOLOGIA DE PIRACICABA
UNIVERSIDADE ESTADUAL DE CAMPINAS

CERTIFICADO

O Comitê de Ética em Pesquisa da FOP-UNICAMP certifica que o projeto de pesquisa "Análise antimicrobiana e proteômica de biofilmes de **Streptococcus mutans** tratados com uma benzofenona poliprenilada extraída da **Rheedia brasiliensis**", protocolo nº **012/2007**, dos pesquisadores **LUCIANA SALLES BRANCO DE ALMEIDA** e **PEDRO LUIZ ROSALEN**, satisfaz as exigências do Conselho Nacional de Saúde – Ministério da Saúde para as pesquisas em seres humanos e foi aprovado por este comitê em 11/04/2007.



The Ethics Committee in Research of the School of Dentistry of Piracicaba - State University of Campinas, certify that the project "**Antimicrobial and proteomic evaluation of Streptococcus mutans biofilms treated with a polyprenylated benzophenone from Rheedia brasiliensis**", register number **012/2007**, of **LUCIANA SALLES BRANCO DE ALMEIDA** and **PEDRO LUIZ ROSALEN**, comply with the recommendations of the National Health Council – Ministry of Health of Brazil for research in human subjects and therefore was approved by this committee at 11/04/2007.

Cinthia Pereira Machado Tabchouy
Profa. Cinthia Pereira Machado Tabchouy
 Secretária
 CEP/FOP/UNICAMP

Prof. Jacks Jorge Júnior
Prof. Jacks Jorge Júnior
 Coordenador
 CEP/FOP/UNICAMP

Nota: O título do protocolo aparece como fornecido pelos pesquisadores, sem qualquer edição.
 Notice: The title of the project appears as provided by the authors, without editing.

6.3 Anexo 3: Certificado do Comitê de Ética na Experimentação Animal.

 UNICAMP	Universidade Estadual de Campinas Instituto de Biologia	 CEEA-IB-UNICAMP
--	--	--

**Comissão de Ética na Experimentação Animal
CEEA-IB-UNICAMP**



CERTIFICADO

Certificamos que o Protocolo nº 963-1, sobre "AVALIAÇÃO DAS ATIVIDADES ANTITUMORAL, ANTIMICROBIANA E DO CONTROLE DA DOR, RELACIONADAS ÀS PATOLOGIAS ORAIS DAS PLANTAS DA FAMÍLIA GUTTIFERAE" sob a responsabilidade de Prof. Dr. Pedro Luiz Rosalen / Ramiro Mendonça Murata / Regiane Yatsuda está de acordo com os Princípios Éticos na Experimentação Animal adotados pelo Colégio Brasileiro de Experimentação Animal (COBEA), tendo sido aprovado pela Comissão de Ética na Experimentação Animal (CEEA)-IB-UNICAMP em reunião de 22 de março de 2006.

CERTIFICATE

We certify that the protocol nº 963-1, entitled "EVALUATION OF THE ANTITUMORAL, ANTIMICROBIAL AND OF THE CONTROL OF THE PAIN ACTIVITY, RELATED TO THE ORAL PATHOLOGIES OF FAMILIA GUTTIFERAE'S PLANTS", is in agreement with the Ethical Principles for Animal Research established by the Brazilian College for Animal Experimentation (COBEA). This project was approved by the institutional Committee for Ethics in Animal Research (State University of Campinas - UNICAMP) on March 22, 2006.

Campinas, 22 de março de 2006.

 _____ Prof. Dra. Ana Maria A. Guaraldo Presidente	 _____ Fátima Alonso Secretária Executiva
--	--

<p>CEEA/IB - Unicamp Caixa Postal 6109 13083-970 Campinas, SP - Brasil</p>	<p>Telefone: (19) 3788-6359 Telefax: (19) 3788-6356 E-mail: ceea@cemib.unicamp.br http://www.ib.unicamp.br/institucional/ceea/index.htm</p>
--	--

6.4 Anexo 4: E-mail de confirmação de aceite do artigo referente ao Capítulo 1.

Date: Dec 07, 2007
To: "Pedro Luiz Rosalen" rosalen@fop.unicamp.br
From: "Phytomedicine" h.wagner@cup.uni-muenchen.de
Subject: Your Submission

Ms. Ref. No.: PHYMED-D-07-00281R1

Title: Antimicrobial activity of *Rheedia brasiliensis* and 7-epiclusianone against *Streptococcus mutans*
Phytomedicine

Dear Dr. Rosalen,

I am pleased to inform you that your paper "Antimicrobial activity of *Rheedia brasiliensis* and 7-epiclusianone against *Streptococcus mutans*" has been accepted for publication in Phytomedicine.

Thank you for submitting your work to Phytomedicine.

Yours sincerely,

Silvia Bächer
Editorial Office
Phytomedicine

For any technical queries about using EES, please contact Elsevier Author Support at authorsupport@elsevier.com

Global telephone support is available 24/7:

For The Americas: +1 888 834 7287 (toll-free for US & Canadian customers)

For Asia & Pacific: +81 3 5561 5032


For Europe & rest of the world: +353 61 709190

6. 5 Anexo 5: Declaração dos autores referente a direitos autorais.

Declaração

As cópias de artigos de minha autoria ou de minha co-autoria, já publicados ou submetidos para publicação em revistas científicas ou anais de congressos sujeitos a arbitragem, que constam da minha Dissertação/Tese de Mestrado/Doutorado, intitulada “Atividade antimicrobiana dos extratos da *Rheedia brasiliensis* e potencial anticâncer de seu composto bioativo”, não infringem os dispositivos da Lei n.º 9.610/98, nem o direito autoral de qualquer editora.

Piracicaba, 29/02/2008



Autor: LUCIANA SALLES BRANCO DE ALMEIDA
RG n.º 35360595-6



Orientador: PEDRO LUIZ ROSALEN
RG n.º 11185975

6. 6 Anexo 6: Declaração da revista *Phytomedicine* referente a direitos autorais.

Contact Author Support
Print

JOURNAL PUBLISHING AGREEMENT

YOUR DETAILS

Article: Antimicrobial activity of *Rheedia brasiliensis* and 7-epiclusianone against *Streptococcus mutans*
 Corresponding author: Dr. Pedro Luiz Rosalen
 Journal: Phytomedicine
 Our Reference: PHYMED50450
 PII: S0944-7113(07)00316-9
 DOI: 10.1016/j.phymed.2007.12.003

YOUR STATUS

I am one author signing on behalf of all co-authors of the manuscript

FUNDING

The underlying research reported in the article was not funded by any of the listed funding bodies

DATA PROTECTION

I do not wish to receive news, promotions and special offers about products and services from Elsevier GmbH and its affiliated companies worldwide.

ASSIGNMENT OF PUBLISHING RIGHTS

I hereby assign to Elsevier GmbH the copyright in the manuscript identified above (government authors not electing to transfer agree to assign a non-exclusive licence) and any supplemental tables, illustrations or other information submitted therewith that are intended for publication as part of or as a supplement to the manuscript (the "Article") in all forms and media (whether now known or hereafter developed), throughout the world, in all languages, for the full term of copyright, effective when and if the article is accepted for publication. This transfer includes the right to provide the Article in electronic and online forms and systems.

RETENTION OF RIGHTS FOR SCHOLARLY PURPOSES

I understand that I retain or am hereby granted (without the need to obtain further permission) rights to use certain versions of the Article for certain scholarly purposes, as described and defined below ("Retained Rights"), and that no rights in patents, trademarks or other intellectual property rights are transferred to the journal.

The Retained Rights include the right to use the Pre-print or Accepted Authors Manuscript for Personal Use, Internal Institutional Use and for Scholarly Posting; and the Published Journal Article for Personal Use and Internal Institutional Use.

AUTHOR WARRANTIES / ETHICS AND DISCLOSURE

I affirm the Author Warranties noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, the Ethics in Publishing policy, and Conflicts of Interest disclosure. For further information see the journal home page or elsevier.com.

Author warranties

The article I have submitted to the journal for review is original, has been written by the stated authors and has not been published elsewhere.

The article is not currently being considered for publication by any other journal and will not be submitted for such review while under review by this journal.

The article contains no libellous or other unlawful statements and does not contain any materials that violate any personal or proprietary rights of any other person or entity.

I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in my article.

If the article was prepared jointly with other authors, I have informed the co-author(s) of the terms of this publishing agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

FUNDING AGENCY REQUIREMENTS AND OTHER POLICIES

I have also been made aware of the journal's policies with respect to funding agency requirements such as the NIH 'PublicAccess' policy, and the rapid publication 'ArticlesInPress' service. See elsevier.com for details.

For more information about the definitions relating to this agreement click [here](#).

I have read and agree to the terms of the Journal Publishing Agreement.

13th December 2007

T-copyright-v12/2007